[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 582
1. Chew GK, Cruickshank ME, Rooney PH, Miller ID, Parkin DE, Murray GI: Human papillomavirus 16 infection in adenocarcinoma of the cervix. Br J Cancer; 2005 Nov 28;93(11):1301-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus 16 infection in adenocarcinoma of the cervix.
  • The impact of the success of organised cervical screening programme results in a steady decline of the incidence of squamous cell carcinoma of the cervix but a concomitant increase in the incidence of the less common histological subtypes, particularly adenocarcinoma of the cervix (ACC).
  • Although Human papillomavirus (HPV) infection is believed to be a necessary cause of cervical cancer, its role in the pathogenesis of ACC is not well established.
  • In this study, the cervical adenocarcinoma cells of a 10-year cohort of women diagnosed with ACC were dissected using the PixCell II Laser Microdissecting System to detect the HPV 16 genome sequence using the real-time quantitative polymerase chain reaction to confirm the presence of HPV DNA within ACC cells.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / genetics. Human papillomavirus 16 / pathogenicity. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gen Virol. 1999 Jul;80 ( Pt 7):1725-33 [10423141.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Methods Mol Biol. 2005;293:27-37 [16028408.001]
  • [Cites] Lancet. 2000 Jun 24;355(9222):2194-8 [10881892.001]
  • [Cites] Mol Pathol. 2000 Apr;53(2):64-8 [10889904.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):11-8 [9556417.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2001 Oct;15(5):663-76 [11563866.001]
  • [Cites] Obstet Gynecol. 1980 Sep;56(3):361-4 [7422175.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 18;84(6):394-8 [1311392.001]
  • [Cites] J Natl Cancer Inst. 1995 Jun 7;87(11):796-802 [7791229.001]
  • [Cites] Lancet. 2001 May 12;357(9267):1490-3 [11377601.001]
  • (PMID = 16265348.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  • [Other-IDs] NLM/ PMC2361519
  •  go-up   go-down


2. Wiesner C, Cendales R, Murillo R, Piñeros M, Tovar S: [Following-up females having an abnormal Pap smear in Colombia]. Rev Salud Publica (Bogota); 2010 Feb;12(1):1-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Seguimiento de mujeres con anormalidad citológica de cuello uterino, en Colombia.
  • OBJECTIVE: Evaluating the opportunity and access to diagnosis and treatment for females having had an abnormal Pap smear (high-grade epithelial lesion and cervical cancer) in Colombia from June 2005 to June 2006.
  • MATERIALS AND METHODS: This was a retrospective appraisal using a semi-closed survey of females having had an abnormal Pap smear with high squamous intraepithelial lesions or cervical cancer living in four Colombian departments.
  • RESULTS: It was found that 27 % of females having high-grade squamous intraepithelial lesion or cervical cancer had no access to any of the diagnostic or therapeutic services.
  • DISCUSSION: Follow-up care after abnormal cytology was very poor and could explain the lack of cervical cancer screening impact in Colombia and in most Latin-American countries.
  • [MeSH-major] Adenocarcinoma / epidemiology. Biopsy / utilization. Cervical Intraepithelial Neoplasia / epidemiology. Cervix Uteri / pathology. Colposcopy / utilization. Health Services Accessibility / statistics & numerical data. Mass Screening. Neoplasms, Squamous Cell / epidemiology. Papanicolaou Test. Uterine Cervical Diseases / epidemiology. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears
  • [MeSH-minor] Adult. Aged. Colombia / epidemiology. Culture. Early Diagnosis. Female. Health Knowledge, Attitudes, Practice. Health Surveys. Humans. Insurance Coverage / statistics & numerical data. Middle Aged. Patient Acceptance of Health Care / statistics & numerical data. Precancerous Conditions / diagnosis. Precancerous Conditions / epidemiology. Precancerous Conditions / pathology. Precancerous Conditions / therapy. Retrospective Studies. Sampling Studies


3. Tawfik El-Mansi M, Cuschieri KS, Morris RG, Williams AR: Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients. Int J Gynecol Cancer; 2006 May-Jun;16(3):1025-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus types 16 and 18 in cervical adenocarcinoma and its precursors in Scottish patients.
  • Our aim was to determine the prevalence of human papillomavirus (HPV) types 16 and 18 in cervical adenocarcinoma (and its precursors) in Scottish patients.
  • We examined 119 cases of invasive adenocarcinoma, 20 cases of adenocarcinoma in situ, and 16 cases of normal glandular epithelium.
  • Our findings support that HPV-16, along with HPV-18, are likely to play a significant role in the pathogenesis of cervical adenocarcinomas and that cervical cancer screening strategies that incorporate oncogenic HPV testing, and prophylactic vaccines that target these types, will be beneficial for the reduction of adenocarcinoma and associated glandular precursors.
  • [MeSH-major] Adenocarcinoma / virology. Human papillomavirus 16 / isolation & purification. Human papillomavirus 18 / isolation & purification. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Carcinoma in Situ / diagnosis. Carcinoma in Situ / virology. Cervical Intraepithelial Neoplasia / epidemiology. Cervical Intraepithelial Neoplasia / etiology. Cervical Intraepithelial Neoplasia / virology. DNA Probes, HPV. Female. Genotype. Humans. Neoplasms, Glandular and Epithelial / epidemiology. Neoplasms, Glandular and Epithelial / etiology. Neoplasms, Glandular and Epithelial / virology. Polymerase Chain Reaction / methods. Polymorphism, Restriction Fragment Length. Prevalence. Scotland / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803480.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Probes, HPV
  •  go-up   go-down


Advertisement
4. Ceballos KM, Shaw D, Daya D: Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis. Am J Surg Pathol; 2006 Mar;30(3):370-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microinvasive cervical adenocarcinoma (FIGO stage 1A tumors): results of surgical staging and outcome analysis.
  • Although studies suggest that microinvasive cervical adenocarcinoma has an excellent prognosis, none has reported treatment-related complications and many have lacked detailed measurement criteria.
  • Our study looks at the rate of lymph node metastases and outcome, including complications, in patients with FIGO 1A1 and 1A2 adenocarcinomas of the cervix.
  • One patient died of metastatic ovarian carcinoma 82 months after her diagnosis of cervical carcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Neoplasm Staging. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery


5. Schmuck RB, Pietzner K, Buckendahl A, Schönlebe J, Sehouli J: Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report. Anticancer Res; 2010 Jul;30(7):2991-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical manifestation of a borderline type ovarian cancer with pseudomyxoma peritonei - a case report.
  • This report describes a special case of BOT with a specific example of the complexity of the differential diagnosis of pseudomyxoma peritonei.
  • Especially the case was simultaneously linked to appendiceal and ovarian cancer.
  • Moreover, this case was exceptional for its unusual manifestation of BOT in the cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis. Pseudomyxoma Peritonei / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Cervix Uteri / pathology. Diagnosis, Differential. Female. Humans. Intestinal Neoplasms / diagnosis. Intestinal Neoplasms / pathology. Neoplasm Invasiveness


6. Kang WD, Kim CH, Cho MK, Kim JW, Kim YH, Choi HS, Kim SM: Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions. Int J Gynecol Cancer; 2009 Jul;19(5):924-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
  • Cervical intraepithelial neoplasia (CIN) 2 is used as the threshold for treatment decisions.
  • This study was conducted to evaluate the clinical efficacy of the Hybrid Capture II assay (HC2) and the human papillomavirus (HPV) DNA chip test (HDC) for detecting HPV in high-grade cervical lesions CIN2 or greater, including adenocarcinoma (CIN2+).
  • Seven hundred forty-one women with abnormal cervical cytology were evaluated with the HC2, the HDC, and histological assessment of the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma, Squamous Cell / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Oligonucleotide Array Sequence Analysis. Papillomaviridae / genetics. Papillomavirus Infections / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Cervix Uteri / virology. DNA, Viral / analysis. DNA, Viral / genetics. Female. Genotype. Humans. Middle Aged. Reagent Kits, Diagnostic. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19574786.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Reagent Kits, Diagnostic
  •  go-up   go-down


7. Aximu D, Azad A, Ni R, Colgan T, Nanji S: A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics. Int J Gynecol Pathol; 2009 Mar;28(2):114-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
  • The histopathologic distinction of cervical adenocarcinoma in situ (AIS) and invasive adenocarcinoma (AC) from some benign endocervical lesions can be challenging.
  • ProEx C immunohistochemical staining was performed on sections from formalin-fixed, paraffin-embedded tissue of 65 cervical tissues including 48 non-neoplastic cervices (normal [n=10], microglandular hyperplasia [n=10], tubal metaplasia [n=11], cervical endometriosis [n=7], reactive endocervix [n=10]) and 17 cervices with glandular malignancy (AIS [n=12] and AC [n=5]).
  • The median and distribution of scores for both prevalence and intensity was compared for AIS versus each of the 5 benign cervical lesions using a Mann-Whitney U test.
  • ProEx C reagent has potential as an adjunctive testing tool in the histopathologic diagnosis of both AIS and AC, particularly in difficult cases with small biopsies or foci of disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cervical Intraepithelial Neoplasia / diagnosis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Minichromosome Maintenance Complex Component 2. Pilot Projects. Reagent Kits, Diagnostic

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188825.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Reagent Kits, Diagnostic; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


8. Ogura K, Ishi K, Matsumoto T, Kina K, Nojima M, Suda K: Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas. Pathol Int; 2006 Jun;56(6):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus localization in cervical adenocarcinoma and adenosquamous carcinoma using in situ polymerase chain reaction: review of the literature of human papillomavirus detection in these carcinomas.
  • Many studies have suggested that human papillomavirus (HPV) infection plays an important role in the carcinogenesis of the cervical adenocarcinoma.
  • However, the prevalence of HPV infection in cervical adenocarcinoma and adenosquamous carcinoma varies among the studies.
  • Cervical adenocarcinoma (24 cases) and adenosquamous carcinoma (16 cases), including the underlying non-neoplastic epithelium were examined for HPV-DNA using in situ polymerase chain reaction (PCR), which enabled visualization of the localization on a glass slide.
  • In adenocarcinoma, HPV-DNA was found in 13 cases (54%) and in eight cases in underlying non-neoplastic epithelium, resulting in a total of 21 positive cases (88%).
  • In adenosquamous carcinoma, HPV-DNA was detected in 12 cases (75%) and and the HPV-DNA localization of each component was pure adenocarcinoma, 28.6%; mixed, 54.5%; and pure squamous cell carcinoma, 83.3%.
  • In the underlying non-neoplastic epithelium, HPV-DNA was found more frequently in the squamous epithelium (73.3%) than the cervical glands (6.3%).
  • In conclusion, HPV-DNA was detected in 54% of adenocarcinoma, and the rate was elevated by HPV localization in the underlying non-neoplastic epithelium.
  • HPV infection in the underlying squamous epithelium might be related to the carcinogenesis, even in cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Adenosquamous / virology. Papillomaviridae / isolation & purification. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / virology


9. Hamer OW, Flint J, Ryan CF, Manos D, Müller NL: Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix. Br J Radiol; 2008 Aug;81(968):e201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoid impaction secondary to mucin-producing metastatic adenocarcinoma of the cervix.
  • Here, we describe an uncommon case of endobronchial metastasis of adenocarcinoma of the cervix causing mucoid impaction owing to mucous production by the tumour cells.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Bronchial Neoplasms / secondary. Uterine Cervical Neoplasms


10. Nagai N, Hirata E, Kusuda T, Mukai K, Arihiro K, Ohama K: Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1187-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix responding to neoadjuvant chemotherapy with docetaxel and cisplatin: a case report.
  • Villoglandular papillary adenocarcinoma (VGPA) of the uterine cervix is a rare neoplasm, and its treatment has rarely been reported.
  • Thus, the combination of docetaxel and cisplatin is suggested to be useful for neoadjuvant chemotherapy of cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Papillary / drug therapy. Adenocarcinoma, Papillary / pathology. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343210.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Csapi B, Hajdú Z, Zupkó I, Berényi A, Forgo P, Szabó P, Hohmann J: Bioactivity-guided isolation of antiproliferative compounds from Centaurea arenaria. Phytother Res; 2010 Nov;24(11):1664-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The antiproliferative effects of n-hexane, chloroform and aqueous methanol extracts prepared from the whole plant of Centaurea arenaria M.B. ex Willd. were investigated against cervix adenocarcinoma (HeLa), breast adenocarcinoma (MCF7) and skin epidermoid carcinoma (A431) cells, using the MTT assay.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 John Wiley & Sons, Ltd.
  • (PMID = 21031625.001).
  • [ISSN] 1099-1573
  • [Journal-full-title] Phytotherapy research : PTR
  • [ISO-abbreviation] Phytother Res
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavonoids; 0 / Plant Extracts; 0 / Sesquiterpenes
  •  go-up   go-down


12. Daniel A, Barreth D, Schepansky A, Johnson G, Capstick V, Faught W: Histologic and clinical significance of atypical glandular cells on pap smears. Int J Gynaecol Obstet; 2005 Dec;91(3):238-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 197(45.2%) patients had a clinically significant diagnosis including 40 with adenocarcinoma in situ (AIS) of the cervix and 48 with endometrial cancer.
  • CONCLUSION: AGC on a Pap smear is frequently associated with a clinically significant diagnosis.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Genital Diseases, Female / pathology. Papanicolaou Test. Vaginal Smears


13. Song SH, Lee JK, Saw HS, Choi SY, Koo BH, Kim A, Yeom BW, Kim I: Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures. J Korean Med Sci; 2006 Aug;21(4):752-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peutz-Jeghers Syndrome with multiple genital tract tumors and breast cancer: a case report with a review of literatures.
  • Her previous medical history was PJS and breast cancer.
  • An ovarian sex cord tumor with annular tubules was incidentally diagnosed together with a minimal deviation adenocarcinoma of the uterine cervix and mucinous metaplasia of both the Fallopian tubal mucosa and the endometrium.
  • The clinical significance of the multiple genital tract tumors and breast cancer associated with PJS is reviewed.
  • [MeSH-major] Breast Neoplasms / pathology. Ovarian Neoplasms / pathology. Peutz-Jeghers Syndrome / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / pathology. Adult. Carcinoma, Ductal, Breast / complications. Carcinoma, Ductal, Breast / pathology. Endometrium / pathology. Fallopian Tubes / pathology. Female. Humans. Korea. Metaplasia. Sex Cord-Gonadal Stromal Tumors / complications. Sex Cord-Gonadal Stromal Tumors / pathology


14. Li F, Awale S, Tezuka Y, Kadota S: Cytotoxic constituents of propolis from Myanmar and their structure-activity relationship. Biol Pharm Bull; 2009 Dec;32(12):2075-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thirteen cycloartane-type tritepenes (1-13) and four prenylated flavanones (14-17) isolated from propolis collected in Myanmar, were evaluated for their cytotoxic activity against a panel of six different cancer cell lines; three murine cancer cell lines (colon 26-L5 carcinoma, B16-BL6 melanoma, and Lewis lung carcinoma) and three human cancer cell lines (lung A549 adenocarcinoma, cervix HeLa adenocarcinoma and HT-1080 fibrosarcoma).
  • In addition, (2S)-5,7-dihydroxy-4'-methoxy-8,3'-diprenylflavanone (14) exhibited strong cytotoxicity against all the tested cancer cell lines with the IC(50) values ranging from 14.0 to 26.4 microM.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952433.001).
  • [ISSN] 1347-5215
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Flavanones; 0 / Triterpenes; 511-64-8 / cycloartane; 9009-62-5 / Propolis
  •  go-up   go-down


15. Gudleviciene Z, Didziapetriene J, Suziedelis K, Lapkauskaite L: [Investigation of human papillomavirus, its types and variants]. Medicina (Kaunas); 2005;41(11):910-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cervical cancer is one of the most common cancers in Lithuania.
  • It is the fourth cancer in women according to the morbidity.
  • The incidence rate of cervical cancer has been increasing in Lithuania since 1992.
  • One of the important risk factor for cervical cancer is human papillomavirus (HPV) infection.
  • The aim of this study is to compare the prevalence of human papillomavirus among cervical cancer patients and women with cervical intraepithelial lesions and healthy women, to determine its types and HPV 16 variants.
  • Polymerase chain reaction and DNA sequencing were used for analysis of specimens taken from cervix uteri.
  • Human papillomavirus was detected in 92.7% of cervical cancer patients and in 26.7% of control women (p<0.0001).
  • HPV 16 (55.8% in squamous cell carcinoma patients and 35.3% in cervical adenocarcinoma patients) and its European HPV 16 L83V variant were detected more frequently in cervical cancer patients.
  • [MeSH-major] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. Cervix Uteri / virology. Human papillomavirus 16. Papillomaviridae / isolation & purification. Papillomavirus Infections / epidemiology. Uterine Cervical Neoplasms / virology


16. Schmidt D, Horn LC, Kommoss F: [Neuroendocrine carcinomas of the cervix]. Pathologe; 2005 Jul;26(4):262-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neuroendocrine carcinomas of the cervix].
  • [Transliterated title] Neuroendokrine Karzinome der Cervix uteri.
  • Neuroendocrine carcinomas of the cervix are rare.
  • They either occur in pure form or in combination with adenocarcinoma or squamous cell carcinoma.
  • [MeSH-major] Neuroendocrine Tumors / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Age Distribution. Aged. Carcinoma, Squamous Cell / pathology. Female. Humans. Prognosis


17. Baydar DE, Himmetoglu C: Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix. Pathology; 2008 Jun;40(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Test and Teach. Abnormal glands in the uterine cervix Part 1. Diagnosis: Ectopic prostate tissue in the uterine cervix.
  • [MeSH-major] Cervix Uteri / pathology. Choristoma / pathology. Prostate. Uterine Cervical Diseases / pathology
  • [MeSH-minor] Acid Phosphatase. Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prostate-Specific Antigen / metabolism. Protein Tyrosine Phosphatases / metabolism. Uterine Cervical Neoplasms / diagnosis


18. Nola M, Tomicic I, Dotlic S, Morovic A, Petrovecki M, Jukic S: Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters. Croat Med J; 2005 Jun;46(3):397-403
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of uterine cervix -- prognostic significance of clinicopathologic parameters.
  • AIM: To investigate prognostic significance of several clinicopathologic parameters in patients with adenocarcinoma of the uterine cervix.
  • CONCLUSION: Our data showed that in patients with adenocarcinoma of the uterine cervix the nuclear grade, clinical stage, and architectural grade of the tumor represent the most important prognostic parameters.
  • [MeSH-major] Adenocarcinoma / mortality. Uterine Cervical Neoplasms / mortality


19. McCluggage WG, Young RH: Immunohistochemistry as a diagnostic aid in the evaluation of ovarian tumors. Semin Diagn Pathol; 2005 Feb;22(1):3-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aspects of immunohistochemistry (IHC), which are useful in the diagnosis of ovarian tumors (mostly neoplasms but also a few tumor-like lesions), are discussed.
  • IHC for neuroendocrine markers may assist in the diagnosis of primary and metastatic carcinoid tumor.
  • The broad differential diagnosis of glandular neoplasms with an endometrioid-pseudoendometrioid morphology, or mucinous cell type, has been the subject of much exploration in recent years, particularly the distinction between primary and metastatic neoplasms.
  • The well-known CK7 positive, CK20 negative phenotype of primary endometrioid carcinoma, and the converse profile in most metastatic large intestinal adenocarcinomas with a pseudoendometrioid morphology, has been much publicized but albeit an appropriate supportive adjunct in many cases, exceptions from the typical staining pattern may be encountered.
  • The rare differential of metastatic cervical adenocarcinoma versus primary ovarian mucinous or endometrioid carcinoma may be aided by strong p16 staining of the former.
  • Staining for alpha-fetoprotein may aid in confirming the diagnosis of endometrioid-like (and hepatoid) variants of yolk sac tumor.
  • As in tumor pathology in general, various markers may be crucial in the diagnosis of small round cell tumors of the ovary, and familiar markers of epithelial, lymphoid, leukemic, and melanocytic neoplasms may assist in the analysis of high grade tumors with a poorly differentiated carcinoma, lymphoma-granulocytic sarcoma, malignant melanoma differential.
  • [MeSH-major] Immunohistochemistry. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Neoplasm Metastasis. Ovarian Cysts / diagnosis. Ovarian Follicle / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512597.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 115
  •  go-up   go-down


20. Tantbirojn P, Triratanachat S, Trivijitsilp P, Niruthisard S: Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens. J Med Assoc Thai; 2008 Sep;91(9):1313-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between adenocarcinoma in both endocervical and endometrial specimens from fractional curettage and pathologic findings in subsequent hysterectomy specimens.
  • OBJECTIVE: To evaluate the hysterectomy specimen findings in the patients who underwent fractional curettage (F&C) with presence of adenocarcinoma in both endocervical and endometrial specimens.
  • MATERIAL AND METHOD: Forty-one patients who had adenocarcinoma in both endocervical and endometrial specimens from F&C and underwent subsequent hysterectomy for surgical staging without pre-operative radiotherapy or chemotherapy at King Chulalongkorn Memorial Hospital between 1999 and 2007 were evaluated Histologic slides from both F&C and hysterectomy specimens were reviewed and assessed All cases of endometrial adenocarcinoma with cervical involvement (stage 2) in hysterectomy specimens were also assessed and compared to the results in F&C specimens.
  • RESULTS: Fifteen patients (36.6%) with both positive endocervical and endometrial specimens from F&C were diagnosed as endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Only 34.1% of cases were endometrial carcinomas with cervical involvement.
  • In the 35 cases with endometrial carcinoma stage 2, 60% had adenocarcinoma in both endocervical and endometrial specimens from F&C.
  • CONCLUSION: In the patients who had adenocarcinoma in both endocervical and endometrial specimens from fractional curettage, the most common final pathological diagnosis from hysterectomy specimens was endometrial adenocarcinoma within uterine cavity with lower uterine segment involvement.
  • Therefore, only 60% of endometrial carcinoma stage 2 revealed positive adenocarcinoma in both endocervical and endometrial specimens from fractional curettage.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Dilatation and Curettage. Endometrial Neoplasms / pathology. Endometrium / pathology. Hysterectomy


21. Wang Z, Zhang T, Hu H, Zhang H, Yang Z, Cui L, He W: Targeting solid tumors via T cell receptor complementarity-determining region 3delta in an engineered antibody. Cancer Lett; 2008 Dec 18;272(2):242-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Moreover, immunotoxin OT3-DT, CDR3delta-grafted antibody OT3 chemically conjugated with diphtheria toxin (DT) showed the anti-tumor effect on the growth of several solid tumors including OEC, cervix adenocarcinoma, hepatocellular carcinoma, and rectum adenocarcinoma to various extents in nude mice.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18782650.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Complementarity Determining Regions; 0 / Receptors, Antigen, T-Cell, gamma-delta
  •  go-up   go-down


22. Baek KH, Lee HJ, Kim MS, Kim YS, Seong M, Lee EJ, Lee MY: Molecular cloning of rHAUSP encoding a deubiquitinating enzyme in rat testis. Oncol Rep; 2006 Jan;15(1):173-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The over-expression of rHAUSP induced cell death of cervical adenocarcinoma cells.


23. Connolly TP, Evans AC: Atypical Papanicolaou smear in pregnancy. Clin Med Res; 2005 Feb;3(1):13-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical glandular cells (AGC) in Papanicolaou (Pap) smears can be associated with premalignant and malignant cervical and endometrial lesions.
  • Positive diagnosis of endocervical adenocarcinoma in situ resulted in a risk-informed decision to proceed with a cold knife conization of the cervix.
  • Final pathology showed complete resection of the lesion with negative margins and an additional area of squamous dysplasia (cervical intraepithelial neoplasia, grade II to III).
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adult. Biopsy. Cervical Intraepithelial Neoplasia / diagnosis. Female. Humans. Pregnancy. Pregnancy Complications, Neoplastic / diagnosis. Pregnancy Complications, Neoplastic / surgery


24. Zanagnolo V, Magrina JF: Robotic radical trachelectomy after supracervical hysterectomy for cut-through endometrial adenocarcinoma stage IIB: a case report. J Minim Invasive Gynecol; 2009 Sep-Oct;16(5):655-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic radical trachelectomy after supracervical hysterectomy for cut-through endometrial adenocarcinoma stage IIB: a case report.
  • A 58-year-old patient with incidental finding of a stage IIB G1 endometrial adenocarcinoma after a supracervical hysterectomy underwent robotic radical trachelectomy, bilateral pelvic lymphadenectomy, and ileal resection with anastomosis.
  • We suggest use of the terms partial radical trachelectomy for fertility preservation procedures and radical trachelectomy after subtotal hysterectomy for the complete radical removal of the cervix.
  • [MeSH-major] Adenocarcinoma / surgery. Cervix Uteri / surgery. Endometrial Neoplasms / surgery. Hysterectomy / methods. Robotics
  • [MeSH-minor] Female. Humans. Incidental Findings. Lymph Node Excision. Middle Aged. Uterine Hemorrhage / surgery

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19835816.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kos M, Sarkanj-Golub R, Cupić H, Balicević D: [The correlation of inflammation and epithelial changes in the Pap smears of cervix uteri]. Acta Med Croatica; 2005;59(4):297-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The correlation of inflammation and epithelial changes in the Pap smears of cervix uteri].
  • A modification of The Bethesda System classification of cytologic findings of uterine cervix named Zagreb 1990 has been accepted in Croatia as a unique classification, the use of which has begun after the publication and printing of the new, uniform method of cytologic examination.
  • AIM: The aim of this study was to assess the number and type of cytologic abnormalities of uterine cervix classified according to Zagreb 1990, on routinely examined Pap smears during the 6-year period, and to investigate the connection of these abnormalities with lower genital tract infections.
  • A total of 59901 Pap smears (patients aged 17-79) were routinely examined: the cytopathologic diagnosis of CIN I or higher recorded in 3664 (6.12%) of them.
  • Endocervical adenocarcinoma was cytologically diagnosed in only 0.0055% of all Pap smears examined.
  • It is concluded that inflammation very likely contributes to the development of precancerous lesions of the cervix, HPV and Chlamydia showing strongest correlation, at least in a part of our population.
  • [MeSH-major] Cervix Uteri / pathology. Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adolescent. Adult. Aged. Epithelium / pathology. Female. Humans. Infection / complications. Infection / diagnosis. Inflammation. Middle Aged. Uterine Cervical Diseases / complications. Uterine Cervical Diseases / microbiology


26. Nieuwenhuizen L, Khalil MK, Venkatesh N, Othman NH: Endometrial and endocervical secretion: the search for histochemical differentiation. Anal Quant Cytol Histol; 2006 Apr;28(2):87-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: A total of 90 cases representing nonneoplastic cervix, non-neoplastic endometrium, endocervical adenocarcinoma and endometrial adenocarcinoma were stained with toluidine blue (TB); methylene blue (MB); mucicarmine (MUC); periodic acid-Schiff before and after diastase digestion (PAS, PAS-D); Alcian blue, pH 2.5 (AB); and periodic acid-Schiff after Alcian blue, pH 2.5 (PAB).
  • There is statistical difference (p < 0.05) in the color of the epithelium and secretions between the non-neoplastic cervix and endometrium.
  • The staining in endocervical adenocarcinoma and endometrial carcinoma was predominantly present in both apical and cytoplasmic locations compared to their non-neoplastic counterparts (endocervix, p = 0.003; endometrium, p = 0.049).


27. Ergünay K, Misirlioğlu M, Firat P, Tuncer ZS, Tuncer S, Yildiz I, Ustaçelebi S: [Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities]. Mikrobiyol Bul; 2008 Apr;42(2):273-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection and typing of human papilloma virus by polymerase chain reaction and hybridization assay in cervical samples with cytological abnormalities].
  • Certain mucosa-tropic human papillomavirus (HPV) types are associated with carcinoma of the uterine cervix or its precursor lesions.
  • In addition to cytological screening, early diagnosis and treatment of cervical carcinoma rely on sensitive detection and typing of HPV isolates.
  • In this study, HPV detection and typing were performed in the cervical samples of patients with abnormal cytological evaluation.
  • Forty randomly-selected cervical samples that comprise 18 ASC-US (Aypical Squamous Cells of Undetermined Significance), four AG-US (Aypical Glandular cells of Undetermined Significance), one ASC-H (Atypical Squamous Cells-can not exclude HSIL), one HSIL (High-grade Intraepithelial Lesion), 14 LSIL (Low-grade Intraepithelial Lesion), one adenocarcinoma and one squamous cell carcinoma, obtained by a commercial liquid-based cytology system (ThinPrep Pap Smear Method, Cytyc, USA), were included to the study.
  • [MeSH-major] Cervix Uteri / virology. Papillomaviridae / classification. Papillomaviridae / isolation & purification. Uterine Cervical Dysplasia / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Adenocarcinoma / virology. Carcinoma, Squamous Cell / virology. DNA, Viral / analysis. Female. Humans. Nucleic Acid Hybridization. Polymerase Chain Reaction / methods


28. Niwa T, Yoshida T, Doiuchi T, Ito K, Nakayama H, Odagiri K, Inoue T: Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy. Br J Radiol; 2008 Aug;81(968):659-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors predicting tumour regression in locally advanced cervical adenocarcinoma treated with balloon-occluded intra-arterial chemotherapy.
  • We retrospectively assessed the factors that may impede tumour reduction of locally advanced cervical adenocarcinoma treated with balloon-occluded arterial infusion chemotherapy (BOAI) as initial therapy.
  • BOAI was performed via uterine arteries in 21 patients, and via the anterior division or main trunk of the internal iliac artery (when the uterine arteries were obscured) in 10 patients.
  • Internal iliac arterial infusion significantly correlated with "no response" compared with uterine arterial infusion (p<0.001).
  • These data suggest that uterine arteries being obscured to arterial infusion may be associated with a poor response to BOAI for cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Uterine Cervical Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628334.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


29. McCluggage WG, Shah R, Connolly LE, McBride HA: Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2. Int J Gynecol Pathol; 2008 Jan;27(1):92-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal-type cervical adenocarcinoma in situ and adenocarcinoma exhibit a partial enteric immunophenotype with consistent expression of CDX2.
  • Most cases of cervical adenocarcinoma in situ (AIS) and adenocarcinoma are of the usual or endocervical type.
  • However, intestinal types of AIS and adenocarcinoma exist.
  • With an intestinal-type adenocarcinoma in the cervix, the question may arise as to whether one is dealing with a primary cervical neoplasm or direct or secondary spread from an intestinal adenocarcinoma.
  • In organs such as the ovary, urinary bladder, esophagus, and gallbladder, intestinal-type glandular epithelium often expresses enteric markers, but this has hardly been studied in the cervix.
  • The purpose of this study was to investigate whether intestinal-type AIS and adenocarcinoma in the cervix express enteric markers and to ascertain whether these antibodies are of value in the distinction from a metastatic intestinal adenocarcinoma.
  • We compared the immunophenotype of these lesions with that of usual-type AIS and adenocarcinomain the cervix.
  • Cases included were AIS of usual type (n = 6), primary cervical adenocarcinoma of usual type (n = 6), AIS of intestinal type (n = 21), primary cervical adenocarcinoma of intestinal type (n = 3), primary cervical adenocarcinoma with signet ring cells (n = 2), and colorectal adenocarcinoma involving the cervix (n = 5).
  • All usual cervical adenocarcinomas were diffusely CK7 and p16 positive, and all were immunoreactive with CEA.
  • The 3 cases of primary cervical intestinal-type adenocarcinoma were diffusely CK7 positive, focally or diffusely positive with CK20 and CDX2, and focally positive with CEA.
  • The foci of signet ring cells in the 2 primary cervical adenocarcinomas were diffusely CK7 and p16 positive and negative with CK20 and CDX2.
  • Colorectal adenocarcinomas involving the cervix were typically diffusely positive with CK20, CEA, and CDX2; negative with CK7; and negative or focally positive with p16.
  • Intestinal types of cervical AIS and adenocarcinoma exhibit a partial enteric immunophenotype, usually with diffuse expression of CDX2 and, in some cases, staining with CK20.
  • Although there is immunophenotypic overlap, focal staining with CK20 together with diffuse CK7 and sometimes p16 positivity helps to distinguish intestinal types of cervical adenocarcinoma from involvement by a colorectal adenocarcinoma; CEA and CDX2 are of no value in this regard.
  • Using a set of cases of AIS diagnosed in a single institution over a 7-year period (77 usual type; 13 intestinal type), intestinal type was more likely to be associated with early invasive adenocarcinoma than usual type (31% vs 17%), suggesting that intestinal differentiation may be a risk factor for invasion in premalignant cervical glandular lesions.
  • [MeSH-major] Adenocarcinoma / metabolism. Homeodomain Proteins / biosynthesis. Intestinal Neoplasms / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / biosynthesis. Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Immunophenotyping. Keratin-20 / biosynthesis. Keratin-7 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156982.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Carcinoembryonic Antigen; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


30. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM: Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol; 2009 Jun;33(6):914-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor.
  • Determining the primary site of a uterine adenocarcinoma can be problematic in hysterectomy specimens due to the overlapping morphology of endocervical adenocarcinomas and endometrial carcinomas, particularly when both the corpus (usually lower uterine segment) and endocervix are involved and precursor lesions are lacking or difficult to distinguish from intramucosal spread of carcinoma from one site to the other.
  • Both preferential extension of endocervical adenocarcinomas into the endometrium (rather than deep cervical stroma) and myometrial invasion derived from the endometrial component are rarely encountered; to our knowledge, these unusual patterns of spread have not been detailed in prior reports.
  • Clinicopathologic features of 10 endocervical adenocarcinomas (9 pure, 1 adenosquamous) with prominent endometrial or endomyometrial involvement were evaluated.
  • Six cases had limited amounts of tumor in the cervix proper, with depths of invasion no greater than 5 mm in 4 and only adenocarcinoma in situ in 2.
  • Four cases had cervical stromal invasion of more than 5 mm but all of these had greater amounts of horizontal extension into endometrium or endomyometrium.
  • Five tumors were originally diagnosed as primary endometrial carcinoma with either cervical extension or concurrent endocervical adenocarcinoma in situ.
  • HPV DNA was detected in both the cervical and corpus components in all tumors and all exhibited diffuse/strong p16 expression and decreased or absent expression of hormone receptors.
  • These ancillary techniques are useful for clarifying the origin of uterine adenocarcinomas when morphologic features and tumor location are equivocal.
  • These cases illustrate that dominant uterine corpus involvement (endometrial or endomyometrial) by primary endocervical adenocarcinoma can lead to misclassification as primary endometrial adenocarcinoma with cervical extension (Fédération Internationale de Gynécologie et d'Obstétrique stage II), especially when endometrial extension of endocervical adenocarcinoma simulates complex atypical hyperplasia.
  • A subset of misclassified endocervical adenocarcinomas may account for some HPV-positive uterine carcinomas reported as primary endometrial carcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Receptors, Steroid / biosynthesis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Diagnosis, Differential. Endometrium / metabolism. Endometrium / pathology. Endometrium / virology. Female. Humans. Immunohistochemistry. In Situ Hybridization. Middle Aged. Papillomaviridae. Papillomavirus Infections / diagnosis. Papillomavirus Infections / metabolism. Papillomavirus Infections / pathology. Receptors, Estrogen / biosynthesis. Receptors, Progesterone / biosynthesis


31. Martin A, Torrent A: Laparoscopic nerve-sparing radical trachelectomy: surgical technique and outcome. J Minim Invasive Gynecol; 2010 Jan-Feb;17(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY OBJECTIVE: To assess the feasibility of the laparoscopic approach in fertility-preserving and radical surgery of cervical cancer in young patients.
  • SETTING: Hospital Son Llatzer, Palma de Mallorca, Spain.
  • PATIENTS: Nine women with early cervical cancer.
  • MEASUREMENTS AND MAIN RESULTS: Data for 9 consecutive women undergoing laparoscopic nerve-sparing radical trachelectomy because of FIGO IA2 (n=2) or FIGO IB1 (n=7) infiltrating cervical carcinoma of the squamous type (n=6) or adenocarcinoma (n=3) were analyzed.
  • CONCLUSIONS: Laparoscopic nerve-sparring radical trachelectomy may be an alternative in fertility-preserving surgery for cervical cancer in centers in which specialization in radical vaginal surgery is lacking.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Cervix Uteri / surgery. Laparoscopy / methods. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AAGL. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20129330.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Stanojkovic TP, Zizak Z, Mihailovic-Stanojevic N, Petrovic T, Juranic Z: Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J Exp Clin Cancer Res; 2005 Sep;24(3):387-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The present work examines the effects of beta and alpha1-adrenoceptor antagonist carvedilol, and angiotensin converting enzyme (ACE) inhibitor captopril, on in vitro growth of tumor cell lines derived from breast tumor (MDA-MB-361), melanoma (Fem-x), cervix adenocarcinoma (HeLa) and human myelogenous leukemia (K562).
  • The order of sensitivity of various human cell lines to carvedilol's antiproliferative action was: myelogenous leukemia K562 (IC50 = 22.66 +/- 2.14 micromol), > cervix carcinoma HeLa (IC50 = 30.56 +/- 5.16 micromol), > melanoma Fem-x (IC50 = 32.17 +/- 5.75 micromol), > breast tumor MDA-MB-361 (IC50 = 35.04 +/- 2.95 micromol).
  • Understanding the action of these established and clinically accepted agents could provide a basis for design of improved therapeutic regimens in the treatment of cancer diseases.

  • Hazardous Substances Data Bank. CAPTOPRIL .
  • Hazardous Substances Data Bank. CARVEDILOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270525.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors; 0 / Carbazoles; 0 / Propanolamines; 0K47UL67F2 / carvedilol; 9G64RSX1XD / Captopril
  •  go-up   go-down


33. Sharpless KE, Schnatz PF, Mandavilli S, Greene JF, Sorosky JI: Dysplasia associated with atypical glandular cells on cervical cytology. Obstet Gynecol; 2005 Mar;105(3):494-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplasia associated with atypical glandular cells on cervical cytology.
  • Most women aged younger than 35 years had a squamous abnormality, whereas women aged 35 years or older had a greater diversity of squamous and glandular lesions and accounted for all cases of endometrial cancer, adenocarcinoma in situ, and cervical adenocarcinoma.
  • [MeSH-major] Cervix Uteri / pathology. Uterine Cervical Dysplasia / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Uterine Cervical Neoplasms / pathology. Vaginal Smears


34. Kuo KT, Liang CW, Hsiao CH, Lin CH, Chen CA, Sheu BC, Lin MC: Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma. Mod Pathol; 2006 Dec;19(12):1570-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of BRG-1 repressed expression of CD44s in cervical neuroendocrine carcinoma and adenocarcinoma.
  • Neuroendocrine carcinomas of the uterine cervix are rare tumors with early metastases, highly aggressive clinical behavior, and poor clinical outcome.
  • We have examined the expression of the standard CD44 (CD44s) by immunohistochemical stains in the paraffin-embedded cervical neoplasm tissue of 17 cases of primary cervical neuroendocrine carcinoma, 28 cases of cervical adenocarcinoma, and 50 cases of cervical squamous cell carcinoma.
  • Loss of CD44s expression was found in 16 of 17 neuroendocrine carcinomas, 14 of 28 adenocarcinomas, and three of 50 squamous cell carcinomas.
  • Loss of BRG-1 expression was observed in 12/16, 6/14, and 1/3 CD44s-negative neuroendocrine carcinomas, adenocarcinomas, and squamous cell carcinomas, respectively.
  • This study suggests that loss of the CD44s molecule may imply special biological behaviors of cervical neuroendocrine carcinomas, and loss of expression of BRG-1 may contribute to this.
  • [MeSH-major] Antigens, CD44 / metabolism. Carcinoma, Neuroendocrine / metabolism. Carcinoma, Squamous Cell / metabolism. DNA Helicases / metabolism. Down-Regulation. Nuclear Proteins / metabolism. Transcription Factors / metabolism. Uterine Cervical Neoplasms / metabolism


35. Marnitz S, Schmittel A, Bolbrinker J, Schmidt FP, Fons G, Kalache K, Schneider A, Köhler C: The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum. Fertil Steril; 2009 Nov;92(5):1748.e1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The therapeutic management of a twin pregnancy complicated by the presence of cervical cancer, following laparoscopic staging and chemotherapy, with an emphasis on cisplatin concentrations in the fetomaternal compartments amnion fluid, umbilical cord, and maternal serum.
  • OBJECTIVE: To evaluate the feasibility, toxicity, and pharmacokinetics in the maternal and fetal compartments during chemotherapy in a pregnant patient with cervical cancer.
  • PATIENT: A 35-year-old woman was diagnosed with an adenocarcinoma FIGO stage IB1 of the cervix uteri at 14 weeks' gestation with twin pregnancy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Cisplatin / therapeutic use. Pregnancy, Multiple. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / pathology


36. Choi JS, Shin S, Jin YH, Yim H, Koo KT, Chun KH, Oh YT, Lee WH, Lee SK: Cyclin-dependent protein kinase 2 activity is required for mitochondrial translocation of Bax and disruption of mitochondrial transmembrane potential during etoposide-induced apoptosis. Apoptosis; 2007 Jul;12(7):1229-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies have suggested that upregulation of Cyclin A-dependent protein kinase 2 (Cdk2) activity is an essential event in apoptotic progression and the mitochondrial permeability transition in human cancer cells.
  • Here, we show that upregulated Cyclin A/Cdk2 activity precedes the proteolytic cleavage of PARP and is correlated with the mitochondrial translocation of Bax and the loss of mitochondrial transmembrane potential (Deltapsim) during etoposide-induced apoptosis in human cervical adenocarcinoma (HeLa) cells.

  • Hazardous Substances Data Bank. ETOPOSIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252195.001).
  • [ISSN] 1360-8185
  • [Journal-full-title] Apoptosis : an international journal on programmed cell death
  • [ISO-abbreviation] Apoptosis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin A; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / bcl-2-Associated X Protein; 6PLQ3CP4P3 / Etoposide; EC 2.4.2.30 / PARP1 protein, human; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


37. Bilton R, Mazure N, Trottier E, Hattab M, Déry MA, Richard DE, Pouysségur J, Brahimi-Horn MC: Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1alpha and is not induced by hypoxia or HIF. J Biol Chem; 2005 Sep 2;280(35):31132-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we show that the ARD1 mRNA and protein levels are not regulated by hypoxia in several human tumor cell lines, including cervical adenocarcinoma HeLa cells, fibrosarcoma HT1080 cells, adenovirus-transformed human kidney HEK293 cells, and human breast cancer MCF-7 cells.

  • SciCrunch. OMIM: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Biol Chem. 2006 Jun 2;281(22):15592
  • (PMID = 15994306.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / HIF1A protein, human; 0 / Hif1a protein, mouse; 0 / Hypoxia-Inducible Factor 1; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / endothelial PAS domain-containing protein 1; EC 2.3.1.- / Acetyltransferases; EC 2.3.1.88 / N-Terminal Acetyltransferase A; EC 2.3.1.88 / N-Terminal Acetyltransferase E; EC 2.3.1.88 / NAA10 protein, human
  •  go-up   go-down


38. Alphandery C, Dagrada G, Frattini M, Perrone F, Pilotti S: Neuroendocrine small cell carcinoma of the cervix associated with endocervical adenocarcinoma: a case report. Acta Cytol; 2007 Jul-Aug;51(4):589-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine small cell carcinoma of the cervix associated with endocervical adenocarcinoma: a case report.
  • BACKGROUND: Small-cell carcinoma (SCC) of the cervix is an uncommon member of the neuroendocrine group of cervical carcinomas that is frequently intermixed with a non-SCC component in the form of an adenocarcinoma (ADC) or squamous carcinoma.
  • CASE: Colposcopy revealed a cervical mass in a 41-year-old woman and a Pap smear the presence of some tumor cells from SCC, which was confirmed by subsequent biopsy.
  • The cervical samples showed areas of endocervical ADC adjacent to and intermixed with the SCC.
  • CONCLUSION: SCC of the cervix is a rare but distinct HR-HPV-18-related cervical carcinoma often intermixed with a clonally related non-small cell component consisting of an ADC or squamous carcinoma.
  • The presence of SCC tumor cells in a cervical smear should prompt a search for malignant glandular or squamous tumor cells.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Neuroendocrine Tumors / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Antigens, CD56 / metabolism. Biopsy. Cervix Uteri / pathology. Chromogranin A / metabolism. Chromosomes, Human, Pair 17 / genetics. Chromosomes, Human, Pair 18 / genetics. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Female. Humans. In Situ Hybridization, Fluorescence. Microsatellite Repeats / genetics. Papanicolaou Test. Synaptophysin / metabolism. Vaginal Smears


39. Han YH, Moon HJ, You BR, Park WH: The anti-apoptotic effects of caspase inhibitors on propyl gallate-treated HeLa cells in relation to reactive oxygen species and glutathione levels. Arch Toxicol; 2009 Sep;83(9):825-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, we evaluated the anti-apoptotic effects of caspase inhibitors on PG-treated human cervix adenocarcinoma HeLa cells in relation to the changes of reactive oxygen species (ROS) and glutathione (GSH) levels.

  • Hazardous Substances Data Bank. PROPYL GALLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19434396.001).
  • [ISSN] 1432-0738
  • [Journal-full-title] Archives of toxicology
  • [ISO-abbreviation] Arch. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / Annexin A5; 0 / Antioxidants; 0 / Caspase Inhibitors; 0 / Enzyme Inhibitors; 0 / Oligopeptides; 0 / Reactive Oxygen Species; 0 / benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone; 0 / benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonyl-leucyl-glutamyl-histidyl-aspartic acid fluoromethyl ketone; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 8D4SNN7V92 / Propyl Gallate; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 8; EC 3.4.22.- / Caspase 9; GAN16C9B8O / Glutathione
  •  go-up   go-down


40. Djordjevic B, Clement-Kruzel S, Atkinson NE, Malpica A: Nodal endosalpingiosis in ovarian serous tumors of low malignant potential with lymph node involvement: a case for a precursor lesion. Am J Surg Pathol; 2010 Oct;34(10):1442-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We first examined the frequency of nodal endosalpingiosis in 30 OSLMP cases, 30 cervical adenocarcinoma cases, and 30 endometrial endometrioid adenocarcinoma cases.
  • The rate of nodal endosalpingiosis was significantly higher in OSLMP cases (33%) compared with both cervical (0%, P<0.0001) and endometrial tumor cases (3%, P=0.0015).
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Uterine Cervical Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20871218.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Martínez-Palones JM, Gil-Moreno A, Pérez-Benavente MA, Garcia-Giménez A, Xercavins J: Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis? Gynecol Oncol; 2005 Apr;97(1):292-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer: a true port-site metastasis?
  • BACKGROUND: We present a case of umbilical metastasis after laparoscopic retroperitoneal paraaortic lymphadenectomy for cervical cancer.
  • CASE: A 59-year-old woman with stage IIIB cervical adenocarcinoma underwent laparoscopic paraaortic lymphadenectomy as well as a conventional laparoscopy to assess the presence of peritoneal carcinomatosis.
  • Seven months after completion of chemoradiotherapy, the patient presented a 2.5-cm umbilical tumor involving the trocar tract together with recurrence of the cervical mass.
  • Histological examination of the excised umbilical mass showed recurrence of the cervical adenocarcinoma, with strong peritumoral CD31 immunocytochemical expression.
  • [MeSH-major] Abdominal Neoplasms / secondary. Adenocarcinoma / secondary. Neoplasm Seeding. Umbilicus / pathology. Uterine Cervical Neoplasms / pathology


42. Nara M, Hashi A, Murata S, Kondo T, Yuminamochi T, Nakazawa K, Katoh R, Hoshi K: Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection. Gynecol Oncol; 2007 Aug;106(2):289-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular endocervical glandular hyperplasia as a presumed precursor of cervical adenocarcinoma independent of human papillomavirus infection.
  • OBJECTIVES: The aim of this study was to investigate differences in the process of carcinogenesis between adenocarcinoma coexistent with LEGH and conventional adenocarcinoma.
  • METHODS: Using the surgical pathology files of patients who visited the University of Yamanashi Hospital, Yamanashi Central Hospital and Kofu Municipal Hospital between 1996 and 2005, pathological diagnoses were reevaluated based on criteria for the diagnosis of LEGH by Nucci et al.
  • As for the cases including adenocarcinoma with LEGH: (a) we created a map showing position of the LEGH component and adenocarcinoma component and squamo-columnar junction (SCJ) in HE-stained specimens, (b) immunohistochemical staining was performed using antibodies to CEA, HIK1083 and p53, and (c) detection of HPV DNA was performed using PCR and in situ hybridization (ISH).
  • RESULTS: Endocervical adenocarcinoma was observed coexistent with LEGH in 5 cases (19.2%). (a) LEGH was located in a remote place from the SCJ.
  • Sizes of lesions in the 5 cases ranged from 18 to 35 mm in width and 7 to 16 mm in depth. (b) HIK1083 was diffusely immunopositive in the cytoplasm of LEGH component and focal immunopositive in 4 cases with adenocarcinoma component.
  • Immunopositivity for CEA was seen in the cytoplasm of adenocarcinoma component in 4 cases.
  • Immunopositivity for p53 was seen in adenocarcinoma component nuclei in 2 cases. (c) HPV DNA was not detected using PCR and ISH in either LEGH or adenocarcinoma components.
  • CONCLUSIONS: The present study suggests that clear differences exist in the process of carcinogenesis between adenocarcinoma associated with LEGH and conventional adenocarcinoma.
  • LEGH may represent a precursor of cervical adenocarcinoma independent of HPV infection.
  • As LEGH displays characteristics of precancerous mucinous adenocarcinoma, surgical treatment should be considered for LEGH growing beyond a certain size.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Neoplasms, Glandular and Epithelial / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


43. Yang Y, Chen L, Han BS, Xu CM, Pan HZ: [Construction and expression of various human prion proteins mutants with modified N-glycosylation sites in mammalian cells]. Sheng Wu Gong Cheng Xue Bao; 2006 May;22(3):373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To study the biological function of the N-glycosylation modification of prion proteins (PrP), various eukaryotic expression vectors for the mutants with N-glycosylation modification of human PrP had been constructed and expressed.
  • With site-direct mutation technique, human PRNP gene was mutated and the obtained mutants were subcloned into eukaryotic expressing plasmid pcDNA3.1 and transiently expressed in Hela cervical adenocarcinoma cell.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755913.001).
  • [ISSN] 1000-3061
  • [Journal-full-title] Sheng wu gong cheng xue bao = Chinese journal of biotechnology
  • [ISO-abbreviation] Sheng Wu Gong Cheng Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glycosylation End Products, Advanced; 0 / Mutant Proteins; 0 / Prions
  •  go-up   go-down


44. Yuan YV, Walsh NA: Antioxidant and antiproliferative activities of extracts from a variety of edible seaweeds. Food Chem Toxicol; 2006 Jul;44(7):1144-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dietary Laminaria and Porphyra sp. have been reported to reduce the risk of intestinal or mammary cancer in animal studies.
  • Thus, in the present study, we evaluated the effect of red alga, dulse (Palmaria palmata) and three kelp (Laminaria setchellii, Macrocystis integrifolia, Nereocystis leutkeana) extracts on human cervical adenocarcinoma cell line (HeLa cells) proliferation using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay.

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554116.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols
  •  go-up   go-down


45. Acién P, Acién M, Sánchez-Ferrer ML: Müllerian anomalies "without a classification": from the didelphys-unicollis uterus to the bicervical uterus with or without septate vagina. Fertil Steril; 2009 Jun;91(6):2369-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENT(S): Six women with uterine malformation.
  • RESULT(S): We have included examples of cases presenting with didelphys uterus with normal cervix, didelphys uterus with septate cervix, and bicornuate (or didelphys) uterus with septate cervix and vagina versus septate uterus with double cervix and vagina, septate bicervical uterus with isthmic communication, and normal simplex uterus with septate cervix and vagina.
  • Therefore, for a more appropriate classification of the uterine malformations, even if the same degrees of fusion, resorption, and development defects are used, a separate classification should be made for each superior and inferior uterine segment.
  • [MeSH-major] Cervix Uteri / abnormalities. Mullerian Ducts / abnormalities. Uterus / abnormalities. Vagina / abnormalities
  • [MeSH-minor] Abnormalities, Multiple / surgery. Adenocarcinoma / surgery. Adult. Aged. Cesarean Section. Female. Humans. Hysterectomy. Middle Aged. Pregnancy. Reproductive Techniques, Assisted. Uterine Neoplasms / surgery

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18367185.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Choi SJ, Brylev KA, Xu JZ, Mironov YV, Fedorov VE, Sohn YS, Kim SJ, Choy JH: Cellular uptake and cytotoxicity of octahedral rhenium cluster complexes. J Inorg Biochem; 2008 Nov;102(11):1991-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cellular uptake behavior of a novel class of octahedral rhenium cluster compounds, hexahydroxo complexes K(4)[{Re(6)S(8)}(OH)(6)].8H(2)O (1) and K(4)[{Re(6)Se(8)}(OH)(6)].8H(2)O (2), was evaluated in human cervical adenocarcinoma HeLa cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18783832.001).
  • [ISSN] 1873-3344
  • [Journal-full-title] Journal of inorganic biochemistry
  • [ISO-abbreviation] J. Inorg. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chelating Agents; 0 / Organometallic Compounds; 7440-15-5 / Rhenium
  •  go-up   go-down


47. Kim SS, Won SJ, Kim NJ, Yoo JK, Bae K, Lee KT: 3-Oxoolean-12-en-27-oic acid isolated from Aceriphyllum rossii induces caspase-8-dependent apoptosis in human promyelocytic leukemia HL-60 cells. Biol Pharm Bull; 2009 Jan;32(1):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 3-OA-treated HL-60 cells and HeLa human cervix adenocarcinoma cells displayed several apoptotic features, such as, DNA fragmentation, DNA laddering by agarose gel electrophoresis, and hypodiploid DNA contents by flow cytometry, and 3-OA also caused the activations of caspase-8, -9 and -3.

  • Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19122287.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Amino Acid Chloromethyl Ketones; 0 / FADD protein, human; 0 / FASLG protein, human; 0 / Fas Ligand Protein; 0 / Fas-Associated Death Domain Protein; 0 / Neuroprotective Agents; 0 / RNA, Messenger; 0 / Tetrazolium Salts; 0 / Thiazoles; 0 / Triterpenes; 0 / benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone; 298-93-1 / thiazolyl blue; EC 3.4.21.- / HABP2 protein, human; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


48. Kasamatsu T, Onda T, Sasajima Y, Kato T, Ikeda S, Ishikawa M, Tsuda H: Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix. Gynecol Oncol; 2009 Dec;115(3):488-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of positive peritoneal cytology in adenocarcinoma of the uterine cervix.
  • OBJECTIVE: A retrospective analysis was carried out to evaluate the prognostic significance of peritoneal cytology in cervical adenocarcinoma.
  • METHODS: The records of 107 patients with FIGO stage IB to IIB cervical adenocarcinoma who underwent hysterectomy were reviewed.
  • Cox model analysis revealed positive cytology [hazards ratio (HR) 6.27, 95% confidence interval (CI) 2.13-18.41], positive lymph node (HR 6.20, 95% CI 1.87-20.57), ovarian metastasis (HR 5.20, 95% CI 1.18-22.82), and histological grade (HR 5.97, 95% CI 2.00-17.78) to be independent adverse risk factors for survival among the factors analyzed (lymph node status, lymph-vascular space invasion, tumor size, depth in cervical wall, pathological parametrial involvement, infiltration to vagina, ovarian metastasis, and histological grade).
  • CONCLUSION: The presence of positive peritoneal cytology appears to be an independent prognostic risk factor in patients with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Peritoneal Cavity / pathology. Uterine Cervical Neoplasms / pathology


49. Niibe Y, Kenjo M, Onishi H, Ogawa Y, Kazumoto T, Ogino I, Tsujino K, Harima Y, Takahashi T, Anbai A, Tsuchida E, Toita T, Takemoto M, Yamashita H, Hayakawa K: High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007). Jpn J Clin Oncol; 2010 Aug;40(8):795-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose-rate intracavitary brachytherapy combined with external beam radiotherapy for stage IIIb adenocarcinoma of the uterine cervix in Japan: a multi-institutional study of Japanese Society of Therapeutic Radiology and Oncology 2006-2007 (study of JASTRO 2006-2007).
  • OBJECTIVE: The current study was a retrospective questionnaire survey of stage IIIb adenocarcinoma of the uterine cervix treated with high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in Japan aimed to investigate the optimal dose on the basis of the biological effective dose and prognostic factors.
  • METHODS: Between 1990 and 2000, 61 patients with stage IIIb adenocarcinoma of the uterine cervix underwent high-dose-rate intracavitary brachytherapy combined with external beam radiation therapy in 19 major hospitals in Japan.
  • Fifty had only adenocarcinoma components and 11 had adenosquamous cell carcinoma components.
  • Stratified by histopathology, the 5-year overall survival rate was 22.1% for adenocarcinoma and 13.6% for adenosquamous cell carcinoma (P = 0.43).
  • CONCLUSIONS: The 5-year overall survival rate of stage IIIb adenocarcinoma of the uterine cervix in this retrospective questionnaire survey was 20.2%.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy / methods. Carcinoma, Adenosquamous / radiotherapy. Uterine Cervical Neoplasms / radiotherapy


50. Bergauer F, Brüning A, Shabani N, Blankenstein T, Jückstock J, Dian D, Mylonas I: Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines. J Mol Histol; 2009 Oct;40(5-6):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibin/activin-betaE subunit in normal and malignant human cervical tissue and cervical cancer cell lines.
  • Recently a novel beta subunit named betaE was described, although it is still unclear if normal or cancerous cervical epithelial cells as well as cervical cancer cell lines can synthesise the novel inhibin-betaE subunit.
  • About 4 normal cervical tissue samples together with 10 specimens of well-differentiated squamous cervical cancer and adenocarcinoma of the cervix were immunohistochemical analyzed.
  • Additionally, two cervical carcinoma cell lines (HeLa and CaSki) were analyzed by immunofluorescence and RT-PCR for the expression of this novel subunit.
  • We demonstrated for the first time an immunolabelling of the inhibin-betaE subunit in normal and malignant cervical tissue, as well as cervical cancer cells.
  • Although the physiological role is still quite unclear in cervical tissue, inhibin-betaE might play important roles in carcinogenesis.
  • Moreover, the synthesis of this subunit in cervical carcinoma cell lines of squamous and glandular epithelial origins also allows the use of these cell lines in elucidating its functions in cervical cancer pathogenesis.
  • However, since the expression of the inhibin-betaE is minimal in HeLa cells as assessed by immunofluorescence and RT-PCR, the CaSki cell line might be a better model for further functional experiments regarding cervical cancer pathogenesis.
  • [MeSH-major] Inhibin-beta Subunits / metabolism. Protein Subunits / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Recent Prog Horm Res. 1988;44:1-34 [3064204.001]
  • [Cites] Histochem Cell Biol. 2009 Jul;132(1):33-8 [19363681.001]
  • [Cites] Mol Cell Endocrinol. 2002 Aug 30;194(1-2):117-22 [12242034.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jun;272(1):59-66 [15309402.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1304-14 [19231155.001]
  • [Cites] Carcinogenesis. 2003 Nov;24(11):1801-9 [12949049.001]
  • [Cites] Acta Histochem. 2009;111(4):360-5 [19195690.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):14-7 [17320281.001]
  • [Cites] Oncol Rep. 2005 Jan;13(1):81-8 [15583806.001]
  • [Cites] Endocrinology. 2003 Aug;144(8):3497-504 [12865331.001]
  • [Cites] Hum Reprod Update. 2002 Nov-Dec;8(6):529-41 [12498423.001]
  • [Cites] Biochem Biophys Res Commun. 1995 May 16;210(2):581-8 [7755637.001]
  • [Cites] Gynecol Oncol. 2009 Aug;114(2):360-4 [19410282.001]
  • [Cites] Exp Biol Med (Maywood). 2002 Feb;227(2):75-87 [11815670.001]
  • [Cites] Endocr Rev. 2001 Dec;22(6):836-58 [11739336.001]
  • [Cites] Virology. 2009 Feb 20;384(2):260-5 [19135222.001]
  • [Cites] J Mol Endocrinol. 2002 Apr;28(2):137-48 [11932210.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):75-80 [12469187.001]
  • [Cites] Cytokine Growth Factor Rev. 2009 Apr;20(2):153-64 [19261538.001]
  • [Cites] Acta Histochem. 2009;111(4):366-71 [19195688.001]
  • [Cites] Stem Cells. 2005 Apr;23 (4):489-95 [15790770.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4A):1995-2000 [17649811.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Biochim Biophys Acta. 1996 Jun 7;1307(2):145-8 [8679697.001]
  • [Cites] Arch Gynecol Obstet. 2010 Aug;282(2):185-91 [20012305.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Apr;83(4):1194-200 [9543140.001]
  • [Cites] Gynecol Oncol. 1998 Apr;69(1):23-31 [9570994.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jan 17;206(2):608-13 [7826378.001]
  • [Cites] Acta Histochem. 2006;108(1):1-11 [16423381.001]
  • [Cites] Mutat Res. 2006 Nov-Dec;613(2-3):123-37 [16997617.001]
  • [Cites] Histochem Cell Biol. 2004 Nov;122(5):461-71 [15480736.001]
  • [Cites] J Mol Endocrinol. 2000 Jun;24(3):409-18 [10828834.001]
  • [Cites] Nature. 1992 Nov 26;360(6402):313-9 [1448148.001]
  • [Cites] Endocr J. 2005 Apr;52(2):169-75 [15863943.001]
  • [Cites] Cancer J. 2003 Sep-Oct;9(5):348-59 [14690309.001]
  • [Cites] Mol Cell Endocrinol. 2004 Oct 15;225(1-2):77-82 [15451571.001]
  • [Cites] Lancet. 2003 Jun 28;361(9376):2217-25 [12842378.001]
  • [Cites] Oncol Rep. 2007 Jan;17(1):97-104 [17143484.001]
  • [Cites] J Mol Histol. 2006 Jan;37(1-2):43-52 [16670820.001]
  • [Cites] Mol Cell Endocrinol. 2004 Oct 15;225(1-2):73-6 [15451570.001]
  • [Cites] Endocr Pathol. 2006 Spring;17(1):19-33 [16760577.001]
  • [Cites] Mol Cell Biol. 2000 Aug;20(16):6127-37 [10913194.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Nov 21;228(3):669-74 [8941337.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):96-103 [17909904.001]
  • (PMID = 20033758.001).
  • [ISSN] 1567-2387
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / INHBE protein, human; 0 / Protein Subunits; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


51. Hope AJ, Saha P, Grigsby PW: FDG-PET in carcinoma of the uterine cervix with endometrial extension. Cancer; 2006 Jan 1;106(1):196-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in carcinoma of the uterine cervix with endometrial extension.
  • BACKGROUND: The authors wished to determine whether pretreatment pathologic evidence of endometrial invasion correlated with fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) findings and outcomes in patients with carcinoma of the uterine cervix.
  • METHODS: Pretreatment whole body FDG-PET was performed in 58 patients with cervical carcinoma who also underwent pathologic evaluation of the endometrium by biopsy or dilation and curettage.
  • CONCLUSIONS: Endometrial extension in cervical cancer correlated strongly with risk of FDG-PET detected lymph node metastases in this study's population and was associated with a poor prognosis.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Carcinoma, Neuroendocrine / radionuclide imaging. Carcinoma, Squamous Cell / radionuclide imaging. Endometrial Neoplasms / radionuclide imaging. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Carcinoma, Adenosquamous / mortality. Carcinoma, Adenosquamous / radionuclide imaging. Carcinoma, Adenosquamous / secondary. Carcinoma, Adenosquamous / therapy. Cervix Uteri / pathology. Cervix Uteri / radionuclide imaging. Combined Modality Therapy. Disease-Free Survival. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Invasiveness. Positron-Emission Tomography. Prospective Studies. Radiopharmaceuticals. Treatment Outcome


52. Chuang LT, Lerner DL, Liu CS, Nezhat FR: Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer. J Minim Invasive Gynecol; 2008 Nov-Dec;15(6):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing robotic-assisted radical trachelectomy and bilateral pelvic lymphadenectomy in early-stage cervical cancer.
  • A combined pelvic lymphadenectomy with radical vaginal trachelectomy is an alternative to radical hysterectomy in the treatment of young women with cervical cancer desiring fertility preservation.
  • A 30-year-old woman, gravida 1, para 1, desiring fertility preservation was given the diagnosis of invasive adenocarcinoma on cervical cone excision.
  • We hope robotic-assisted radical trachelectomy will become an option for select women with early-stage cervical cancer who desire fertility preservation.
  • [MeSH-major] Adenocarcinoma / surgery. Fertility / physiology. Lymph Node Excision / methods. Robotics. Uterine Cervical Neoplasms / surgery


53. Lee JW, Park JA, Kim SH, Seo JH, Lim KJ, Jeong JW, Jeong CH, Chun KH, Lee SK, Kwon YG, Kim KW: Protein kinase C-delta regulates the stability of hypoxia-inducible factor-1 alpha under hypoxia. Cancer Sci; 2007 Sep;98(9):1476-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present article protein kinase C-delta (PKC-delta) is activated by hypoxia, increases the protein stability and transcriptional activity of HIF-1alpha in human cervical adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608772.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; EC 2.7.11.13 / Protein Kinase C-delta
  •  go-up   go-down


54. Vrdoljak E, Boraska Jelavic T, Saratlija-Novakovic Z, Hamm W: Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri. Eur J Gynaecol Oncol; 2005;26(6):602-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy in the treatment of locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri.
  • The optimal treatment of women with locally advanced adenocarcinoma or adenosquamous carcinoma of the cervix uteri is still undefined.
  • We report a series of four consecutive patients with locally advanced adeno- or adenosquamous carcinomas of the uterine cervix (FIGO Stages IB-IIIB) treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by one to four cycles of consolidation chemotherapy with the same drug combination.
  • Despite the low number of patients in this series we may conclude that concomitant chemobrachyradiotherapy with ifosfamide and cisplatin followed by consolidation chemotherapy with the same drug combination is an efficacious treatment of patients with locally advanced adeno- or adenosquamous carcinomas of the cervix uteri.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brachytherapy. Carcinoma, Adenosquamous / drug therapy. Uterine Cervical Neoplasms / drug therapy


55. Kawauchi S, Kusuda T, Liu XP, Suehiro Y, Kaku T, Mikami Y, Takeshita M, Nakao M, Chochi Y, Sasaki K: Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immunohistochemical study. Am J Surg Pathol; 2008 Dec;32(12):1807-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lobular endocervical glandular hyperplasia a cancerous precursor of minimal deviation adenocarcinoma?: a comparative molecular-genetic and immunohistochemical study.
  • Although lobular endocervical glandular hyperplasia (LEGH) was originally described as a distinct hyperplastic glandular lesion of the uterine cervix, recent studies have raised a question that LEGH may be a cancerous precursor of minimal deviation adenocarcinoma (MDA) and other mucinous adenocarcinomas (MACs) of the uterine cervix.
  • Dual-color fluorescence in situ hybridization confirmed a gain of chromosome 3 fragment in these cervical glandular lesions.
  • Microsatellite instability was rarely detected in these cervical glandular lesions.
  • Our present study results demonstrated a molecular-genetic link between LEGH and cervical mucinous glandular malignancies including MDA and MAC, and are thought to support the hypothesis that a proportion of LEGHs are cancerous precursors of MDA and/or MAC.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Precancerous Conditions / pathology. Uterine Cervical Neoplasms / pathology


56. O'Neill CJ, McCluggage WG: p16 expression in the female genital tract and its value in diagnosis. Adv Anat Pathol; 2006 Jan;13(1):8-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p16 expression in the female genital tract and its value in diagnosis.
  • Diffuse (as opposed to focal) positivity with p16 in the cervix can be regarded as a surrogate marker of the presence of high-risk human papillomavirus (HPV).
  • In cervical squamous lesions, p16 is positive in most high-grade cervical intraepithelial neoplasia (CIN) and in some cases of low-grade CIN, usually those associated with high-risk HPV. p16 may be useful to identify small focal high-grade CIN lesions, to distinguish some cases of CIN involving immature metaplastic squamous epithelium from immature metaplastic squamous epithelium not involved by CIN and to distinguish high-grade CIN from benign mimics.
  • Most cervical carcinomas of squamous, glandular, and small cell type are p16-positive.
  • In cervical glandular lesions, p16 is useful, as part of a panel, in the distinction between adenocarcinoma in situ (diffusely positive) and benign mimics, including tuboendometrial metaplasia and endometriosis, which are usually p16-negative or focally positive. p16 may be used, in combination with other markers, to distinguish between a cervical adenocarcinoma (diffuse positivity) and an endometrioid-type endometrial adenocarcinoma (negative or focally positive).
  • Some uterine serous carcinomas are diffusely positive.
  • In the uterus, p16 positivity is more common and widespread in leiomyosarcomas than leiomyomas, and this may be a useful aid to diagnosis, although problematic uterine smooth muscle neoplasms have not been extensively studied.
  • Metastatic cervical adenocarcinomas in the ovary are usually diffusely p16-positive, and because these may closely mimic a primary ovarian endometrioid or mucinous adenocarcinoma, this may be a valuable diagnostic aid, although p16 expression in primary ovarian adenocarcinomas of these morphologic subtypes has not been widely investigated.
  • Some ovarian serous carcinomas, similar to their uterine counterparts, are p16-positive.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / analysis. Genital Neoplasms, Female / diagnosis
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Carcinoma, Small Cell / chemistry. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Cystadenocarcinoma, Serous / chemistry. Cystadenocarcinoma, Serous / diagnosis. Cystadenocarcinoma, Serous / genetics. Diagnosis, Differential. Endometrial Neoplasms / chemistry. Endometrial Neoplasms / diagnosis. Endometrial Neoplasms / genetics. Female. Genes, p16. Genitalia, Female / chemistry. Genitalia, Female / physiopathology. Humans. Immunohistochemistry. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Proteins / analysis. Tumor Suppressor Proteins / genetics. Uterine Cervical Neoplasms / chemistry. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / genetics. Uterine Neoplasms / chemistry. Uterine Neoplasms / diagnosis. Uterine Neoplasms / genetics. Vulvar Neoplasms / chemistry. Vulvar Neoplasms / classification. Vulvar Neoplasms / diagnosis. Vulvar Neoplasms / genetics

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16462152.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Proteins
  • [Number-of-references] 65
  •  go-up   go-down


57. Luciani S, Bertoletti L, Vergnon JM: [Endoscopic treatment of endobronchial metastases from adenocarcinoma of the uterine cervix]. Rev Mal Respir; 2010 Sep;27(7):759-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Endoscopic treatment of endobronchial metastases from adenocarcinoma of the uterine cervix].
  • [Transliterated title] Traitement endoscopique de métastases endobronchiques d'un adénocarcinome du col utérin.
  • They are very rarely due to uterine cervical cancer.
  • CASE REPORT: We present the extraordinary case of a woman with endobronchial metastases from an adenocarcinoma of the uterine cervix.
  • Pathological analysis of this tumour confirmed the diagnosis and found papilloma virus infection.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Bronchial Neoplasms / secondary. Bronchial Neoplasms / surgery. Bronchoscopy. Uterine Cervical Neoplasms / pathology


58. Sert B: Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes. Int J Med Robot; 2010 Jun;6(2):132-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic port-site and pelvic recurrences after robot-assisted laparoscopic radical hysterectomy for a stage IB1 adenocarcinoma of the cervix with negative lymph nodes.
  • BACKGROUND: Port-site metastasis (PSM) following minimally invasive surgery for gynaecological cancer has been recognized as a potential problem over the last two decades.
  • METHODS: A 60 year-old woman with stage Ib1 adenocarcinoma of the cervix was treated with radical hysterectomy, bilateral salpingo-oophorectomy and bilateral pelvic lymph node dissection, using robot-assisted laparoscopy.
  • CONCLUSION: This is the first case report emphasizing the risk of PSM and early pelvic recurrences in robot-assisted laparoscopic radical hysterectomy and bilateral pelvic lymph node dissection for an early-stage cervical adenocarcinoma patient with negative lymph nodes, histologically examined by immunohistochemical ultrastaging.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adnexa Uteri / pathology. Adnexa Uteri / surgery. Amputation. Endometrial Neoplasms / pathology. Endometrial Neoplasms / secondary. Endometrial Neoplasms / surgery. Female. Follow-Up Studies. Gynecologic Surgical Procedures. Humans. Laparoscopy / methods. Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Neoplasm Staging. Pelvis / pathology. Pelvis / surgery. Recurrence. Time Factors. Treatment Outcome


59. Undurraga M, Petignat P, Pelte MF, Jacob S, Dubuisson JB, Loubeyre P: Magnetic resonance imaging to identify risk of lymph node metastasis in patients with endometrial cancer. Int J Gynaecol Obstet; 2009 Mar;104(3):233-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging to identify risk of lymph node metastasis in patients with endometrial cancer.
  • OBJECTIVE: To assess the value of magnetic resonance imaging (MRI) to identify endometrial cancer patients at risk of lymph node metastasis.
  • METHODS: Retrospective review of data from 108 patients with clinical stage I endometrial cancer who underwent preoperative MRI and were treated surgically.
  • Patients at risk of lymph node metastasis were defined as those who had more than 50% myometrial infiltration or cervical invasion.
  • RESULTS: The mean age of the patients was 69.5 years and most patients had endometrioid cancer.
  • On final pathologic analysis, 59 patients had deep myometrial infiltration or cervical invasion.
  • For diagnosis of deep myometrial infiltration, cervical invasion, or both, MRI sensitivity and specificity were 56% and 85%; 47% and 83%; and 67% and 77%, respectively.
  • CONCLUSION: MRI has limited value in identifying patients with endometrial cancer who are at risk of lymph node metastasis.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Neoplasm Invasiveness / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cervix Uteri / pathology. Confidence Intervals. Female. Humans. Lymph Nodes / pathology. Lymph Nodes / surgery. Middle Aged. Myometrium / pathology. Neoplasm Staging. Predictive Value of Tests. Preoperative Care / methods. Retrospective Studies. Risk. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Endometrial cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036368.001).
  • [ISSN] 1879-3479
  • [Journal-full-title] International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
  • [ISO-abbreviation] Int J Gynaecol Obstet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Nishida M, Nasu K, Takai N, Miyakawa I, Kashima K: Adenoid cystic carcinoma of the uterine cervix. Int J Clin Oncol; 2005 Jun;10(3):198-200
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenoid cystic carcinoma of the uterine cervix.
  • Adenoid cystic carcinoma of the uterine cervix is a rare and peculiar variant of adenocarcinoma.
  • This tumor represents 3% of all primary cervical adenocarcinomas, and it is locally aggressive and capable of metastasis to other organs even in its early stage.
  • Generally, radiotherapy and chemotherapy are chosen as the first treatment, because this cancer is seen most commonly in the elderly.
  • [MeSH-major] Carcinoma, Adenoid Cystic / radiotherapy. Uterine Cervical Neoplasms / radiotherapy


61. Jung YW, Kim SW, Kim S, Kim JH, Cho NH, Kim JW, Kim YT: Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma. Eur J Obstet Gynecol Reprod Biol; 2010 Jan;148(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and clinical relevance of cyclooxygenase-1 and -2 expression in stage IIB cervical adenocarcinoma.
  • OBJECTIVE: The objective of this study was to determine the relationship between cyclooxygenase (COX)-1 and -2 and prognosis in patients diagnosed with FIGO stage IIB cervical adenocarcinoma who underwent concurrent chemoradiotherapy.
  • STUDY DESIGN: Twenty-three patients diagnosed with stage IIB cervical adenocarcinoma and treated with concurrent chemoradiotherapy between 1990 and 1995 were included in this study.
  • COX-2 expression was associated with poor response to treatment and cancer-related death (P=0.043 and 0.012, respectively).
  • CONCLUSION: Only COX-2 was found to be a potent prognostic factor in patients treated with concurrent chemoradiotherapy for stage IIB cervical adenocarcinoma.
  • However, further studies with more samples are needed to definitely demonstrate the relationship between COX expression and cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cyclooxygenase 1 / biosynthesis. Cyclooxygenase 2 / biosynthesis. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836124.001).
  • [ISSN] 1872-7654
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 1.14.99.1 / Cyclooxygenase 1; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


62. Pukkala E, Malila N, Hakama M: Socioeconomic differences in incidence of cervical cancer in Finland by cell type. Acta Oncol; 2010;49(2):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Socioeconomic differences in incidence of cervical cancer in Finland by cell type.
  • INTRODUCTION: We studied variation in incidence of cervix cancer during 1971-1995 among Finnish women born in 1906 to 1945 by social class and cell type.
  • MATERIAL AND METHODS: The Finnish Cancer Registry data were linked to the 1970 Population Census, which included social class data.
  • There were 0.8 million individuals in the cohort under follow-up, with 5,102 squamous cell cancers and 573 cases of cervical adenocarcinoma diagnosed after the census date.
  • RESULTS: Incidence of squamous cell cancer was more than two-fold in the lowest social class (standardized incidence ratio (SIR) 1.29, 95% CI 1.21-1.36) as compared with the highest one (SIR 0.59, 0.51-0.66), while there was no association between social class and risk on adenocarcinoma (SIR 1.07, 0.87-1.28 and 1.08, 0.79-1.45, respectively).
  • DISCUSSION: Oncogenic HPV is regarded as the necessary cause of all types of cervix cancer.
  • Lack of association between adenocarcinoma and social class makes the HPV-etiology of this cell type less credible than that of squamous cell cancer.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Squamous Cell / epidemiology. Uterine Cervical Neoplasms / epidemiology


63. Numnum TM, Makhija S, Lu B, Wang M, Rivera A, Stoff-Khalili M, Alvarez RD, Zhu ZB, Curiel DT: Improved anti-tumor therapy based upon infectivity-enhanced adenoviral delivery of RNA interference in ovarian carcinoma cell lines. Gynecol Oncol; 2008 Jan;108(1):34-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hec1 (Highly Expressed in Cancer gene 1) has recently been shown to play an important role in the proper segregation of chromosomes during mitosis.
  • Recently, an adenovirus delivery system carrying RNA interference (RNAi) of Hec1 has been reported in a cervical adenocarcinoma model.
  • METHODS: Two adenoviruses (Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3), along with a negative control (Ad-siRNA-GAPDH.F5/3), were created using homologous recombination.
  • RESULTS: QPCR demonstrated a 2-log viral infectivity enhancement with Ad-siRNA-Hec1.F5/3 over Ad-siRNA-Hec1.
  • QPCR at 72 h revealed mRNA knockdown induced by Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cells, respectively (71%/60%, and 32%/78% mRNA knockdown compared to negative control).
  • Western blot revealed translational inhibition induced by both Hec1 Ads with the least knockdown seen with Ad-siRNA-GAPDH.F5/3.
  • MTS assay indicated increased cell death 8 days post-infection with Ad-siRNA-Hec1 and Ad-siRNA-Hec1.F5/3 in SKOV3.ip1 and HEY cell lines, respectively (75% vs. 35% and 43% vs. 12% viable cells).
  • Crystal violet staining revealed increased cell death with Ad-siRNA-Hec1.F5/3 in all tested cell lines.
  • The infectivity-enhanced adenovirus as delivery mechanism shows potential application in future gene therapy models of RNAi in ovarian cancer.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Ther. 2003 Sep;8(3):449-58 [12946318.001]
  • [Cites] Mol Ther. 2003 Nov;8(5):762-8 [14599809.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4339-45 [14625284.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Aug;40(4):342-8 [15188458.001]
  • [Cites] Mol Ther. 2004 Jul;10(1):162-71 [15233951.001]
  • [Cites] Mol Cancer Ther. 2004 Jul;3(7):833-8 [15252144.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):785-95 [15350374.001]
  • [Cites] J Virol. 1968 May;2(5):430-9 [4301313.001]
  • [Cites] Cancer Res. 2003 May 1;63(9):2088-95 [12727824.001]
  • [Cites] Curr Biol. 2003 Jan 8;13(1):41-6 [12526743.001]
  • [Cites] Science. 2002 Sep 27;297(5590):2267-70 [12351790.001]
  • [Cites] Mol Ther. 2001 Jan;3(1):28-35 [11162308.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7297-301 [7638184.001]
  • [Cites] Genes Dev. 1999 Dec 15;13(24):3191-7 [10617568.001]
  • [Cites] Gene Ther. 1997 Sep;4(9):961-8 [9349433.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Cancer Gene Ther. 1999 Jul-Aug;6(4):367-72 [10419055.001]
  • [Cites] Gynecol Oncol. 2005 Feb;96(2):341-8 [15661219.001]
  • [Cites] Mol Biol Cell. 2005 Feb;16(2):519-31 [15548592.001]
  • [Cites] Gene Ther. 2006 Jan;13(1):1-7 [16121206.001]
  • [Cites] Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8829-36 [16361572.001]
  • [Cites] Mol Biol Rep. 2006 Mar;33(1):43-9 [16636916.001]
  • [Cites] Br J Cancer. 2006 May 8;94(9):1300-10 [16622456.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):595-603 [16865275.001]
  • [Cites] Int J Oncol. 2006 Nov;29(5):1319-29 [17016667.001]
  • [Cites] Curr Oncol Rep. 2006 Nov;8(6):441-7 [17040622.001]
  • [Cites] Cancer Biol Ther. 2006 Dec;5(12):1708-13 [17106249.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1917-26 [12204675.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):275-80 [11801569.001]
  • (PMID = 18061250.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA083821-08; United States / NCI NIH HHS / CA / R01 CA083821; United States / NCI NIH HHS / CA / R01 CA083821-08
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NDC80 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ NIHMS38788; NLM/ PMC2744403
  •  go-up   go-down


64. Coupienne I, Piette J, Bontems S: How to monitor NF-kappaB activation after photodynamic therapy. Methods Mol Biol; 2010;635:79-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • For several years, photodynamic therapy (PDT) has emerged as an attractive alternative approach for the treatment of different affections involving various forms of cancer and an increasing number of reports have highlighted the activation of the NF-kappaB following PDT treatment.
  • As a working model we will present results obtained from a 5-aminolevulinic acid-PDT treatment on cervix adenocarcinoma cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552341.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / I-kappa B Proteins; 0 / NF-kappa B; 0 / Photosensitizing Agents; 0 / Synaptotagmin I; 139874-52-5 / NF-kappaB inhibitor alpha; 88755TAZ87 / Aminolevulinic Acid; EC 1.13.12.- / Luciferases
  •  go-up   go-down


65. Wang QX, Wang SZ, Liu J: [Clinical significance on atypical cervical glandular cytology]. Zhonghua Yi Xue Za Zhi; 2009 Oct 27;89(39):2779-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance on atypical cervical glandular cytology].
  • OBJECTIVE: To determine the pathological features and clinical implications of atypical glandular cells of undetermined significance (AGC) in cervical cytological results.
  • METHODS: All 87 cases of cervical cytological examinations with AGC were identified by a computerized database in our patient population.
  • The authors analyzed the cervical histopathological results by colposcopic biopsy, dilatation and curettage (D&C), cervical loop electrosurgical excision procedure (LEEP)and follow-ups. RESULTS:.
  • (1) Thirty-five cases (40.23%) had cervical and endometrial neoplasic findings: ten glandular lesions (11.49%) and squamous lesion was present in 25 patients (28.74%). (2) Among 61 patients with Pap smears subclassified as "AGC-not otherwise specified", there were 18 pathological abnormalities.
  • Ten patients with AGC as "adenocarcinoma in situ" or "adenocarcinoma" were of 6 pathological abnormalities. (3) 100% of patients with AGC had both of colposcopic and cytologic follow-ups: 1 case CIN1, 1 case CIN2 and 1 case CIN3. (4) One of 10 patients was younger than 35 years old with CGIN1 and the other 9 patient aged over 35 years old had a greater diversity of glandular lesions.
  • CONCLUSION: A finding of AGC requires both colposcopy and an aggressive workup because of a high rate of cancer and precancerous lesions.
  • Women aged over 35 years old has a greater diversity of glandular lesions and account for most cases of cervical and endometrial adenocarcinoma.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / cytology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


66. Favero G, Lanowska M, Schneider A, Marnitz S, Köhler C: Laparoscopic pelvic lymphadenectomy in a patient with cervical cancer stage Ib1 complicated by a twin pregnancy. J Minim Invasive Gynecol; 2010 Jan-Feb;17(1):118-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic pelvic lymphadenectomy in a patient with cervical cancer stage Ib1 complicated by a twin pregnancy.
  • Cervical cancer is the most frequently observed malignancy during pregnancy.
  • To our knowledge, this is the first report of a twin pregnancy complicated by cancer of the uterine cervix that was successfully treated with laparoscopic pelvic lymphadenectomy and subsequently with neoadjuvant chemotherapy.
  • Cervical adenocarcinoma, grade 2, stage 1b1 with lymphovascular space invasion was diagnosed.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Pregnancy Complications, Neoplastic / surgery. Pregnancy, Multiple. Uterine Cervical Neoplasms / surgery


67. Alpan AS, Zencir S, Zupkó I, Coban G, Réthy B, Gunes HS, Topcu Z: Biological activity of bis-benzimidazole derivatives on DNA topoisomerase I and HeLa, MCF7 and A431 cells. J Enzyme Inhib Med Chem; 2009 Jun;24(3):844-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The compounds were screened via in vitro plasmid superciol relaxation assays using mammalian DNA topoisomerase I and cytostatic assays were carried out against HeLa (cervix adenocarcinoma), MCF7 (breast adenocarcinoma) and A431 (skin epidermoid carcinoma) cells for selected derivatives.
  • [MeSH-minor] Animals. Breast Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Cell Line, Tumor. DNA Topoisomerases, Type I / metabolism. Female. HeLa Cells. Humans. Spectrum Analysis. Structure-Activity Relationship. Uterine Cervical Neoplasms / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18951286.001).
  • [ISSN] 1475-6374
  • [Journal-full-title] Journal of enzyme inhibition and medicinal chemistry
  • [ISO-abbreviation] J Enzyme Inhib Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzimidazoles; 0 / Topoisomerase I Inhibitors; 16656-27-2 / bis-benzimidazole; EC 5.99.1.2 / DNA Topoisomerases, Type I
  •  go-up   go-down


68. Zhao Y, Lin H, Shen D, Xuan Y, Lin Z: Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China. Pathol Int; 2008 Oct;58(10):643-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China.
  • The aim of the present study was to investigate the distribution of HPV genotypes in uterine cervical lesions in Yanbian, northern China.
  • HPV-DNA chip (oligonucleotide microarray) and cervical biopsy were used for 322 women in 1998-2005.
  • All the normal cervical epithelia were negative for HPV.
  • The positive rate of high-risk HPV was 33.9% in cervical intra-epithelial neoplasia (CIN)-1, 51.6% in CIN-2, 57.7% in CIN-3, 66.7% in cervical glandular intra-epithelial neoplasia (CGIN), 91.7% in squamous cell carcinoma (SCC), and 78.6% in adenocarcinoma.
  • HPV-16 was the major type in all CIN and SCC cervical lesions, but in cervical adenocarcinoma HPV-18 was the most common type, and HPV-16 was the second most common type.
  • Several cases of CIN-3, SCC and adenocarcinoma had multiple types of HPV, but there was none in CIN-1/2.
  • In summary, HPV-16 is the type most frequently involved in the development of SCC of the cervix, and this may be helpful for the prediction of the development and progress of CIN-2/3, whereas both HPV-18 and -16 play a prominent role in the development of adenocarcinoma and CGIN of the cervix in Yanbian, northern China.
  • [MeSH-major] Adenocarcinoma / virology. Alphapapillomavirus / genetics. Carcinoma, Squamous Cell / virology. Cervical Intraepithelial Neoplasia / virology. Papillomavirus Infections / virology. Uterine Cervical Neoplasms / virology


69. Brink AA, Zielinski GD, Steenbergen RD, Snijders PJ, Meijer CJ: Clinical relevance of human papillomavirus testing in cytopathology. Cytopathology; 2005 Feb;16(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer of the uterine cervix is the second most common cancer in women worldwide.
  • Currently, cervical screening is based on cytology alone.
  • Because infection with high-risk human papillomavirus types (hrHPVs) is a necessary cause of cervical cancer, it has been postulated that screening might become more efficient when it is based on combined cytology and hrHPV testing.
  • In this review we will discuss the advantages of added HPV tests in cervical cancer screening, as a quality control for false-negative smears, in triage of women with equivocal smears, in follow-up of women treated for CIN3 or cervical cancer and for the detection of cervical adenocarcinoma.
  • [MeSH-major] Papillomaviridae / isolation & purification. Papillomavirus Infections / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / diagnosis. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / therapy. Cytodiagnosis / methods. False Negative Reactions. Female. Humans. Mass Screening. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / prevention & control

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cytopathology. 2005 Feb;16(1):3-6 [15859308.001]
  • (PMID = 15859309.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


70. Tian Q, Lu W, Chen H, Ye F, Xie X: The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women. Int J Gynecol Cancer; 2009 Aug;19(6):1011-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The nonsynonymous single-nucleotide polymorphisms in codon 31 of p21 gene and the susceptibility to cervical cancer in Chinese women.
  • BACKGROUND: It was suggested that single-nucleotide polymorphisms in p21 codon 31 seem to be associated with a variety of human malignancies; very few studies have focused on the association between p21 codon 31 polymorphisms and cervical cancer.
  • This study explored whether p21 codon 31 nonsynonymous single-nucleotide polymorphisms might be associated with an increased risk of cervical cancer development among Chinese women.
  • METHODS: Peripheral blood samples were obtained from patients with cervical cancer (n = 317) and healthy controls (n = 353) for detecting the biallelic polymorphisms at codon 31 of p21 gene by the mismatch amplification mutation assay-polymerase chain reaction.
  • Cervix brush-off samples were obtained from patients with cervical squamous cell carcinoma (SCC) and controls for detection of high-risk human papillomavirus (HR-HPV).
  • RESULTS: The AGA (Arg) allele frequency in patients with cervical SCCs was significantly higher than that in controls.
  • AGA/AGA and AGA/AGC genotypes were more frequently found in cervical SCCs than in controls.
  • There was no significant difference of allele frequency or genotype distribution between cervical adenocarcinomas and controls, or between HR-HPV-positive and HR-HPV-negative groups.
  • CONCLUSIONS: p21 Codon 31 with AGA (Arg) allele is a genetic risk factor of cervical SCC, and the increased risk is probably not caused by increasing host susceptibility to HR-HPV infection.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. Carcinoma, Squamous Cell / genetics. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Polymorphism, Single Nucleotide. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Case-Control Studies. Female. Gene Frequency. Genetic Predisposition to Disease. Genotype. Humans. Mutation, Missense / physiology. Papillomavirus Infections / complications

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820361.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21
  •  go-up   go-down


71. Hussain SK, Sundquist J, Hemminki K: Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database. Int J Cancer; 2008 Apr 15;122(8):1873-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Familial clustering of cancer at human papillomavirus-associated sites according to the Swedish Family-Cancer Database.
  • Familial aggregation of cervical cancer has been demonstrated previously, however aggregation of other human papillomavirus-associated anogenital, upper aerodigestive tract and skin cancers has not been fully characterized.
  • The Swedish Family-Cancer Database, which contains reliable data on cancer incidence and nuclear family linkages for all residents of Sweden between 1958 and 2004, was used to calculate standardized incidence ratios (SIR) and 95% confidence intervals for offspring site-specific cancer risks according to site-specific cancer in sibling and parental probands.
  • Offspring cancer risk was significantly increased when either a sibling or parent was affected at the same site for penile squamous cell carcinoma (SCC, SIR = 7.54), cervical adenocarcinoma (AC, SIR = 2.31), vulvar SCC (SIR = 2.27), skin SCC (SIR = 2.14), rectal AC (SIR = 1.86), in situ cervical SCC (SIR = 1.80), invasive cervical SCC (SIR = 1.77) and upper aerodigestive tract SCC (SIR = 1.57).
  • In situ cervical SCC risk in offspring was strongly influenced by siblings affected with oropharyngeal SCC (SIR = 3.17) and tonsillar SCC (SIR = 1.84).
  • Familial skin SCC was largely unassociated with anogenital or upper aerodigestive tract cancer risk in offspring.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adult. Aged. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. Cluster Analysis. Family. Female. Humans. Incidence. Male. Medical Record Linkage. Middle Aged. Mouth Neoplasms / epidemiology. Odds Ratio. Papillomavirus Infections / complications. Papillomavirus Infections / virology. Pharyngeal Neoplasms / epidemiology. Registries. Sweden / epidemiology. Tonsillar Neoplasms / epidemiology. Tumor Virus Infections / complications. Tumor Virus Infections / virology. Uterine Cervical Neoplasms / epidemiology. Vulvar Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18074353.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Ikeda O, Mizukami N, Murata Y, Arakawa A, Katabuchi H, Okamoto H, Yasunaga T, Tsunawaki A, Yamashita Y: Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma. Cardiovasc Intervent Radiol; 2005 Nov-Dec;28(6):736-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized comparison of intra-arterial chemotherapy versus intra-arterial chemotherapy and gelfoam embolization for treatment of advanced cervical carcinoma.
  • PURPOSE: We evaluated the effects of intra-arterial infusion therapy by comparing the results obtained with a combination of intra-arterial anticancer drugs with and without transcatheter arterial embolization (TAE) in patients with cervical cancer.
  • METHODS: Between April 1999 and March 2003, intra-arterial therapy was administered to 45 patients (mean age 49 years) with cervical cancer.
  • Of these, 18 had stage IIb , 4 had stage IIIa, 19 had stage IIIb, and 4 had stage IVb cancer; the histopathologic types were squamous cell carcinoma (n = 35), adenocarcinoma (n = 8), and adenosquamous carcinoma (n = 2).
  • [MeSH-major] Carcinoma / therapy. Drug Therapy, Combination. Embolization, Therapeutic / methods. Gelatin Sponge, Absorbable / therapeutic use. Hemostatics / therapeutic use. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Cervix Uteri / pathology. Cisplatin / adverse effects. Cisplatin / therapeutic use. Combined Modality Therapy / adverse effects. Combined Modality Therapy / methods. Doxorubicin / adverse effects. Doxorubicin / therapeutic use. Female. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Humans. Infusions, Intra-Arterial / methods. Magnetic Resonance Imaging / methods. Middle Aged. Mitomycin / adverse effects. Mitomycin / therapeutic use. Treatment Outcome


73. Seresini S, Origoni M, Caputo L, Lillo F, Longhi R, Vantini S, Paganoni AM, Protti MP: CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix. Immunology; 2010 Sep;131(1):89-98
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
  • Cervical neoplastic lesions are associated with infection by high-risk human papilloma-viruses (HPV).
  • We previously reported that anti-HPV-18 E6 CD4(+) T cells are present in patients with high-grade HPV-18-expressing cervical lesions but also in 50% of the total consecutive patients tested, independently of the HPV type carried.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Cervical Intraepithelial Neoplasia. Cervix Uteri / virology. DNA-Binding Proteins / immunology. Human papillomavirus 18 / immunology. Oncogene Proteins, Viral / immunology. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / immunology. Adenocarcinoma / pathology. Adenocarcinoma / virology. Adult. Female. Humans. Lymphocyte Activation / immunology. Middle Aged. Papillomavirus Infections / immunology. Papillomavirus Infections / virology. Tumor Virus Infections / immunology. Tumor Virus Infections / virology. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1998 Apr 15;58(8):1700-6 [9563486.001]
  • [Cites] J Natl Cancer Inst. 1997 Sep 3;89(17):1285-93 [9293919.001]
  • [Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]
  • [Cites] J Virol. 1999 Jul;73(7):6166-70 [10364377.001]
  • [Cites] Nat Biotechnol. 1999 Jun;17(6):555-61 [10385319.001]
  • [Cites] Int J Cancer. 1999 Jul 30;82(3):334-7 [10399949.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8761-6 [15574788.001]
  • [Cites] Clin Infect Dis. 2005 Feb 1;40(3):451-7 [15668870.001]
  • [Cites] Int J Cancer. 2005 May 1;114(5):766-78 [15609316.001]
  • [Cites] Eur J Immunol. 2005 Mar;35(3):806-15 [15719368.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):248-59 [15986031.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):950-6 [16152582.001]
  • [Cites] Rev Med Virol. 2006 Mar-Apr;16(2):83-97 [16287204.001]
  • [Cites] Nat Rev Cancer. 2007 Jan;7(1):11-22 [17186016.001]
  • [Cites] J Gen Virol. 2007 May;88(Pt 5):1470-8 [17412975.001]
  • [Cites] Clin Cancer Res. 2007 Apr 15;13(8):2479-87 [17438108.001]
  • [Cites] J Immunol. 2007 Nov 15;179(10):7176-83 [17982110.001]
  • [Cites] Int J Cancer. 2008 Feb 1;122(3):486-94 [17955486.001]
  • [Cites] Clin Vaccine Immunol. 2008 Jun;15(6):937-45 [18448624.001]
  • [Cites] Virology. 2009 Feb 20;384(2):335-44 [19007963.001]
  • [Cites] Oncogene. 2001 Nov 26;20(54):7874-87 [11753670.001]
  • [Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):636-41 [12566307.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] J Gen Virol. 2003 May;84(Pt 5):1063-70 [12692269.001]
  • [Cites] J Virol. 2003 May;77(9):5464-74 [12692247.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):565-71 [14744770.001]
  • [Cites] J Obstet Gynaecol Res. 2004 Apr;30(2):120-9 [15009616.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3301-8 [15161683.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5449-55 [15289354.001]
  • [Cites] Virology. 1998 May 10;244(2):352-64 [9601506.001]
  • (PMID = 20545782.001).
  • [ISSN] 1365-2567
  • [Journal-full-title] Immunology
  • [ISO-abbreviation] Immunology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / E6 protein, Human papillomavirus type 18; 0 / E7 protein, Human papillomavirus type 18; 0 / Oncogene Proteins, Viral
  • [Other-IDs] NLM/ PMC2966761
  •  go-up   go-down


74. Niibe Y, Hayakawa K, Kanai T, Tsunoda S, Arai M, Jobo T, Kuramoto H, Unno N: Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol; 2006;27(1):47-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimal dose for stage IIIB adenocarcinoma of the uterine cervix on the basis of biological effective dose.
  • PURPOSE: Prognosis of uterine cervical adenocarcinoma in locally advanced stage treated with radiation therapy has been considered to be much worse than that of squamous cell carcinoma because the optimal dose for the former one has not been determined.
  • Thus, the current study was performed to investigate the optimal dose for Stage IIIB, locally advanced stage, adenocarcinoma of the uterine cervix on the basis of the biological effective dose (BED).
  • METHODS: One-hundred and seventy-nine patients with Stage IIIB carcinoma of the uterine cervix were treated with curative intended therapy at Kitasato University Hospital between 1976 and 2000.
  • Out of them, 13 patients had an adenocarcinoma component in pathological findings.
  • Nine patients were diagnosed with adenocarcinoma and four patients were diagnosed with adenosquamous cell carcinoma.
  • CONCLUSION: The current study suggested that the optimal dose for Stage IIIB adenocarcinoma of the uterine cervix might be T-BED10 > or = 100 Gy.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Radiotherapy, High-Energy / methods. Salvage Therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy


75. Kietpeerakool C, Srisomboon J, Prompittayarat W, Kanjanavaha P, Peuwsai R, Dheerakul C: Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization? Asian Pac J Cancer Prev; 2006 Oct-Dec;7(4):522-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Can adenocarcinoma in situ of the uterine cervix be predicted before cervical conization?
  • This study was undertaken to determine the effectiveness of the Papanicolaou (Pap) smear, colposcopically-directed biopsy (CDB), and endocervical curettage (ECC) in preconization detection of adenocarcinoma in situ (AIS) of the uterine cervix.
  • Women, whose cervical conization specimens contained adenocarcinoma in situ without any associated invasive lesion at Chiang Mai University Hospital between March 1998 and March 2006, were reviewed.
  • [MeSH-major] Adenocarcinoma / diagnosis. Carcinoma in Situ / diagnosis. Cervix Uteri / pathology. Conization. Uterine Cervical Neoplasms / diagnosis


76. Chaturvedi AK, Kleinerman RA, Hildesheim A, Gilbert ES, Storm H, Lynch CF, Hall P, Langmark F, Pukkala E, Kaijser M, Andersson M, Fossa SD, Joensuu H, Travis LB, Engels EA: Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol; 2009 Feb 20;27(6):967-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix.
  • PURPOSE: Although cervical squamous cell carcinoma (SCC) and adenocarcinoma (AC) are both caused by human papillomavirus (HPV) infection, they differ in cofactors such as cigarette smoking.
  • We assessed whether these cofactor differences translate into differences in second cancer risk.
  • PATIENTS AND METHODS: We assessed second cancer risk among 85,109 cervical SCC and 10,280 AC survivors reported to population-based cancer registries in Denmark, Finland, Norway, Sweden, and the United States.
  • RESULTS: Overall cancer risk was significantly increased among both cervical SCC survivors (n = 10,559 second cancers; SIR, 1.31; 95% CI, 1.29 to 1.34) and AC survivors (n = 920 second cancers; SIR, 1.29; 95% CI, 1.22 to 1.38).
  • Risks of HPV-related and radiation-related cancers were increased to a similar extent among cervical SCC and AC survivors.
  • Although significantly increased in both groups when compared with the general population, risk of smoking-related cancers was significantly higher among cervical SCC than AC survivors (P = .015; SIR for cervical SCC = 2.07 v AC = 1.78).
  • This difference was limited to lung cancer (SIR for cervical SCC = 2.69 v AC = 2.18; P = .026).
  • The increased lung cancer risk among cervical AC survivors was observed for both lung SCC and lung AC.
  • SIRs for second cancers of the colon, soft tissue, melanoma, and non-Hodgkin's lymphoma were significantly higher among cervical AC than SCC survivors.
  • CONCLUSION: The second cancer profiles among cervical SCC and AC survivors mirror the similarities and differences in cofactors for these two histologies.
  • Because smoking is not a cofactor for cervical AC, the increased lung cancer risk suggests a role for additional factors.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Feb;12(2):153-61 [11246844.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1611-22 [18628412.001]
  • [Cites] Lancet. 2002 Mar 30;359(9312):1093-101 [11943256.001]
  • [Cites] J Clin Pathol. 2002 Dec;55(12):885-91 [12461047.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):687-91 [12740919.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):57-65 [12807947.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):814-21 [12910527.001]
  • [Cites] Br J Cancer. 2003 Dec 1;89(11):2078-86 [14647141.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1035-44 [14983500.001]
  • [Cites] Br J Cancer. 2004 May 4;90(9):1787-91 [15150591.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1428-36 [15368331.001]
  • [Cites] J Epidemiol Community Health. 1984 Mar;38(1):85-8 [6707569.001]
  • [Cites] J Natl Cancer Inst. 1985 May;74(5):955-75 [3858584.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):679-88 [3338033.001]
  • [Cites] Gynecol Oncol. 1989 May;33(2):189-92 [2703179.001]
  • [Cites] Gynecol Oncol. 1989 Jun;33(3):340-3 [2722061.001]
  • [Cites] Int J Cancer. 1989 Jul 15;44(1):7-16 [2744900.001]
  • [Cites] Laryngoscope. 1992 Jan;102(1):9-13 [1309932.001]
  • [Cites] Gynecol Oncol. 1993 Dec;51(3):301-6 [8112636.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):442-52 [8625126.001]
  • [Cites] Invest Radiol. 1995 Dec;30(12):724-9 [8748186.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S3-9 [15552776.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Sep;14(9):2191-9 [16172231.001]
  • [Cites] Lung Cancer. 2006 Jan;51(1):21-9 [16337709.001]
  • [Cites] Int J Cancer. 2006 Mar 15;118(6):1481-95 [16206285.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):292-3 [16507820.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 1;98(5):303-15 [16507827.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/11-25 [16949997.001]
  • [Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/35-41 [16950016.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2214-20 [17278095.001]
  • [Cites] Br J Cancer. 2007 Jul 2;97(1):85-91 [17579626.001]
  • [Cites] Anticancer Res. 2007 Jul-Aug;27(4C):2697-704 [17695435.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1634-43 [17971527.001]
  • [Cites] Cancer Res. 2007 Nov 15;67(22):10686-93 [18006810.001]
  • [CommentIn] J Clin Oncol. 2009 Jun 20;27(18):3065-6; author reply 3066-7 [19433676.001]
  • (PMID = 19114696.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2738433
  •  go-up   go-down


77. Lavie O, Segev Y, Peer G, Gutterman E, Sagie S, Auslnader R: Conservative management for villoglandular papillary adenocarcinoma of the cervix diagnosed during pregnancy followed by a successful term delivery: a case report and a review of the literature. Eur J Surg Oncol; 2008 May;34(5):606-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative management for villoglandular papillary adenocarcinoma of the cervix diagnosed during pregnancy followed by a successful term delivery: a case report and a review of the literature.
  • [MeSH-major] Adenocarcinoma, Papillary / surgery. Conization. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery


78. Andersson S, Hellström AC, Angström T, Stendahl U, Auer G, Wallin KL: The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1065-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathologic significance of laminin-5 gamma2 chain expression in cervical squamous carcinoma and adenocarcinoma.
  • Carcinoma of the uterine cervix is one of the most prevalent malignancies among women in developing countries and the third most common type worldwide.
  • Squamous cell carcinoma predominates in the cervix uteri, while adenocarcinoma and adenosquamous carcinomas represent about 10-15% of all cervical cancers.
  • Many studies have confirmed that the human papillomavirus (HPV) is the most important etiologic factor in the development of cervical cancer.
  • The aim of our study was to investigate the expression of the laminin-5 gamma2 chain in primary malignancies of the cervix uteri and to focus on the clinicopathologic significance of the expression of the laminin-5 gamma2 chain in cervical squamous carcinoma and adenocarcinoma with respect to age and survival of the patients.
  • The study consisted of a total of 89 cases of invasive cervical cancer (54 squamous carcinomas and 35 adenocarcinomas).
  • The laminin-5 gamma2 chain was found in 80% of all the squamous carcinoma and in 66% of cervical adenocarcinoma.
  • The univariate analysis in squamous cell carcinoma showed that factors such as the stage of the disease and positive lymph nodes had an impact on the survival of the patients, whereas in the multivariate analysis, only age at diagnosis was an independent prognostic factor.
  • However, in cases with cervical adenocarcinoma, only the stage of the disease was an independent prognostic factor.
  • Our results indicate that the majority of the primary cervical tumors, especially squamous cell carcinoma, showed expression of laminin-5 gamma2 chain immunoreactivity.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Laminin / biosynthesis. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343183.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LAMC2 protein, human; 0 / Laminin
  •  go-up   go-down


79. Othumpangat S, Kashon M, Joseph P: Sodium arsenite-induced inhibition of eukaryotic translation initiation factor 4E (eIF4E) results in cytotoxicity and cell death. Mol Cell Biochem; 2005 Nov;279(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Exposure to arsenic (As) is a risk factor for the development of diabetes, vascular diseases and cancer.
  • We have also investigated the potential cellular mechanisms underlying the As-induced de-regulation of expression of eIF4E that are most likely responsible for the cytotoxicity and cell death induced by As.
  • Exposure of four different human cell lines - HCT15 (colorectal adenocarcinoma), PLC/PR/5 (hepatocellular carcinoma), HeLa (cervical adenocarcinoma) and Chang (likely derived from HeLa cells) to sodium arsenite (NaAsO2) for time intervals up to 24 h resulted in a concentration-dependent cytotoxicity and cell death.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1999 Jul;107(7):593-7 [10379007.001]
  • [Cites] Cell Cycle. 2003 Jul-Aug;2(4):358-68 [12851490.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 May 1;172(3):225-32 [11312651.001]
  • [Cites] Mutat Res. 2003 Jan 10;534(1-2):133-43 [12504762.001]
  • [Cites] Cancer Res. 2000 Jul 1;60(13):3445-53 [10910055.001]
  • [Cites] Mol Cell Biol. 1988 Aug;8(8):3556-9 [3062383.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Cell Physiol. 2002 Jan;190(1):29-37 [11807808.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33968-75 [15178684.001]
  • [Cites] J Biol Chem. 1995 Sep 8;270(36):21176-80 [7673150.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4326-35 [10439040.001]
  • [Cites] J Toxicol Environ Health A. 2000 Jan 28;59(2):119-34 [10653439.001]
  • [Cites] J Cell Mol Med. 2001 Jul-Sep;5(3):221-39 [12067482.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):219-28 [9219560.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]
  • [Cites] Eur J Biochem. 2000 Feb;267(4):1083-91 [10672017.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 2000;19(3):281-6 [10983894.001]
  • [Cites] Science. 1988 Jul 1;241(4861):79-81 [3388020.001]
  • [Cites] Toxicol Appl Pharmacol. 2003 Jan 15;186(2):101-9 [12639501.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24776-80 [10811643.001]
  • [Cites] Oncogene. 2000 Jun 15;19(26):3021-31 [10871854.001]
  • [Cites] J Biol Chem. 2005 Jul 1;280(26):25162-9 [15878868.001]
  • [Cites] Mol Cell Biol. 1991 Nov;11(11):5435-45 [1922056.001]
  • [Cites] Cancer Causes Control. 1997 May;8(3):371-85 [9498900.001]
  • [Cites] Cell Death Differ. 2001 Aug;8(8):841-9 [11526437.001]
  • [Cites] Cancer Res. 1995 Mar 15;55(6):1296-300 [7882325.001]
  • [Cites] Br J Cancer. 1992 Nov;66(5):888-92 [1419632.001]
  • [Cites] Toxicol Lett. 2002 Jul 7;133(1):47-57 [12076509.001]
  • [Cites] J Biol Chem. 2001 Apr 6;276(14):11414-9 [11150309.001]
  • [Cites] Environ Health Perspect. 2000 May;108(5):393-7 [10811564.001]
  • [Cites] Am J Epidemiol. 1998 Apr 1;147(7):660-9 [9554605.001]
  • [Cites] Oncogene. 2000 Mar 9;19(11):1437-47 [10723135.001]
  • [Cites] J Biol Chem. 1985 May 10;260(9):5486-92 [3988764.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7950-8 [14633726.001]
  • [Cites] Toxicol Lett. 2001 Jul 6;122(3):223-34 [11489357.001]
  • [Cites] Carcinogenesis. 1985 Oct;6(10):1421-6 [3840060.001]
  • [Cites] J Toxicol Environ Health B Crit Rev. 1998 Jul-Sep;1(3):199-241 [9644328.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Nov;87(21):8212-6 [2122455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Anal Chem. 1999 Apr 1;71(7):1408-14 [10204040.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1990-5 [11842186.001]
  • [Cites] J Biol Chem. 2001 Aug 3;276(31):29111-5 [11408474.001]
  • [Cites] EMBO J. 1996 Nov 15;15(22):6269-79 [8947050.001]
  • [Cites] Mol Cell Biol. 1996 Nov;16(11):6573-81 [8887686.001]
  • [Cites] Mol Cell Biol. 2002 Mar;22(6):1656-63 [11865045.001]
  • [Cites] Nucleic Acids Res. 1989 Aug 11;17(15):5923-31 [2671936.001]
  • (PMID = 16283521.001).
  • [ISSN] 0300-8177
  • [Journal-full-title] Molecular and cellular biochemistry
  • [ISO-abbreviation] Mol. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Arsenites; 0 / Eukaryotic Initiation Factor-4E; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Sodium Compounds; 0 / Ubiquitin; 136601-57-5 / Cyclin D1; 48OVY2OC72 / sodium arsenite
  •  go-up   go-down


80. Tian Y, Wu P, Luo AY, Xi L, Zhou JF, Ma D: [Expression and significance of Smad2/3 and HPV16 E7 in cervical intraepithelial neoplasia and cervical carcinoma]. Ai Zheng; 2007 Sep;26(9):967-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of Smad2/3 and HPV16 E7 in cervical intraepithelial neoplasia and cervical carcinoma].
  • Human papillomavirus (HPV) is an important carcinogenic agent of cervical cancer.
  • However, their relationship in the genesis of cervical cancer is unclear.
  • This study was to detect the expression of Smad2/3 and HPV16 E7 protein in different cervical lesions, and to explore their possible roles in tumor genesis and progression.
  • METHODS: The expression of Smad2/3 and HPV16 E7 in 20 specimens of chronic cervicitis, 30 specimens of cervical intraepithelial neoplasia (CIN), and 30 specimens of cervical cancer was detected by SP immunohistochemistry.
  • RESULTS: The positive rates of Smad2/3 were significantly lower in cervicitis and CIN than in cervical cancer (50.0% and 73.3% vs. 93.3%, P<0.05), and significantly lower in cervicitis than in CINIII(P<0.05).
  • The positive rates of HPV16 E7 were 60.0% in cervicitis, 66.7% in CIN, and 83.3% in cervical cancer (P>0.05).
  • The expression of Smad2/3 in cervical cancer had no correlation to clinical stage, pathologic classification, histological grade, and lymph node involvement(P>0.05).
  • CONCLUSIONS: Overexpression of Smad2/3 may be involved in the genesis of cervical cancer.
  • It is closely correlated to HPV infection in cervical carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Oncogene Proteins, Viral / metabolism. Smad2 Protein / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Biomarkers, Tumor / metabolism. Cervix Uteri / metabolism. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Papillomavirus E7 Proteins. Smad3 Protein / metabolism. Up-Regulation. Uterine Cervicitis / metabolism

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17927854.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Oncogene Proteins, Viral; 0 / Papillomavirus E7 Proteins; 0 / SMAD2 protein, human; 0 / SMAD3 protein, human; 0 / Smad2 Protein; 0 / Smad3 Protein; 0 / oncogene protein E7, Human papillomavirus type 16
  •  go-up   go-down


81. Kong CS, Beck AH, Longacre TA: A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas. Am J Surg Pathol; 2010 Jul;34(7):915-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas.
  • Endometrial and endocervical adenocarcinomas may seem histologically identical and it can be difficult to determine primary site of origin based on morphology alone.
  • The TMA consisted of 214 endometrial carcinomas, 33 endocervical adenocarcinomas, and 36 problematic cases.
  • The endometrial and endocervical carcinomas represented usual endometrioid and mucinous types, and special variants (uterine serous carcinoma, uterine clear cell carcinoma, minimal deviation endocervical adenocarcinoma, cervical small cell carcinoma, adenoid basal cell carcinoma, mesonephric carcinoma).
  • Using a script written in R, the diagnostic accuracy of all possible combinations of markers was evaluated and it was shown that a 3 marker panel including vimentin, ER, or PR, and an HPV marker (p16, ProExC, or HPV ISH) is optimal for determining site of origin for usual endometrial and endocervical adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Cyclin-Dependent Kinase Inhibitor p16 / analysis. DNA, Viral / analysis. Endometrial Neoplasms / diagnosis. Papillomaviridae / genetics. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. In Situ Hybridization. Papillomavirus Infections / diagnosis. Reproducibility of Results. Tissue Array Analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534993.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007033
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Viral; 0 / Vimentin
  • [Other-IDs] NLM/ NIHMS775595; NLM/ PMC4847142
  •  go-up   go-down


82. Nishio S, Ushijima K, Tsuda N, Takemoto S, Kawano K, Yamaguchi T, Nishida N, Kakuma T, Tsuda H, Kasamatsu T, Sasajima Y, Kage M, Kuwano M, Kamura T: Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma. Cancer Lett; 2008 Jun 8;264(1):36-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cap43/NDRG1/Drg-1 is a molecular target for angiogenesis and a prognostic indicator in cervical adenocarcinoma.
  • This study investigated associations of Cap43 expression with angiogenesis and other clinicopathological factors in cervical adenocarcinoma.
  • The clinical records of 100 women who underwent surgery for cervical adenocarcinoma were reviewed retrospectively.
  • Our results suggest that increased expression of Cap43 is associated with angiogenesis and may be a poor prognostic indicator in women with cervical adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / blood supply. Adenocarcinoma / metabolism. Cell Cycle Proteins / metabolism. Intracellular Signaling Peptides and Proteins / metabolism. Neovascularization, Pathologic. Uterine Cervical Neoplasms / blood supply. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281151.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Intracellular Signaling Peptides and Proteins; 0 / N-myc downstream-regulated gene 1 protein; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


83. Altaf FJ: Cervical cancer screening with pattern of pap smear. Review of multicenter studies. Saudi Med J; 2006 Oct;27(10):1498-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical cancer screening with pattern of pap smear. Review of multicenter studies.
  • OBJECTIVE: To estimate the frequency of abnormal cervical smears and to compare the findings with earlier reported data from Saudi Arabia.
  • The malignant categories were squamous cell carcinoma (0.08%), adenocarcinoma of cervix in situ (0.02%) and invasive (0.04%).
  • Unified national programs for diagnosing cervical precancerous lesions should be established covering different region of the Kingdom to evaluate the magnitude of the problem.
  • [MeSH-major] Papanicolaou Test. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / epidemiology. Vaginal Smears / trends


84. Chang J, Zhang S, Zhou H, Liang JX, Lin ZQ: [Clinical analysis of minimal deviation adenocarcinoma of the cervix: a report of five cases]. Ai Zheng; 2008 Dec;27(12):1310-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of minimal deviation adenocarcinoma of the cervix: a report of five cases].
  • BACKGROUND & OBJECTIVE: The minimal deviation adeno-carcinoma (MDA) of the cervix is a rare disease.
  • This study was to evaluate clinicopathologic features, diagnosis, and treatment of MDA.
  • CONCLUSIONS: Diagnosis of MDA mainly depends on its clinical manifestations and the pathological feature that MDA glands are located deeper than the lower level of normal endocervical glands.
  • [MeSH-major] Adenocarcinoma / therapy. Neoplasm Recurrence, Local. Uterine Cervical Neoplasms / therapy


85. Nijhuis ER, van der Zee AG, in 't Hout BA, Boomgaard JJ, de Hullu JA, Pras E, Hollema H, Aalders JG, Nijman HW, Willemse PH, Mourits MJ: Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery. Int J Radiat Oncol Biol Phys; 2006 Nov 1;66(3):699-705
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gynecologic examination and cervical biopsies after (chemo) radiation for cervical cancer to identify patients eligible for salvage surgery.
  • PURPOSE: The aim of this study was to evaluate efficacy of gynecologic examination under general anesthesia with cervical biopsies after (chemo) radiation for cervical cancer to identify patients with residual disease who may benefit from salvage surgery.
  • METHODS AND MATERIALS: In a retrospective cohort study data of all cervical cancer patients with the International Federation of Gynecology and Obstetrics (FIGO) Stage IB1 to IVA treated with (chemo) radiation between 1994 and 2001 were analyzed.
  • Cervical biopsy samples were taken from patients judged to be operable.
  • In case of residual cancer, salvage surgery was performed.
  • RESULTS: Between 1994 and 2001, 169 consecutive cervical cancer patients received primary (chemo) radiation, of whom 4 were lost to follow-up.
  • CONCLUSIONS: Gynecologic examination under anesthesia 8 to 10 weeks after (chemo) radiation with cervical biopsies allows identification of those cervical cancer patients who have residual local disease, of whom a small but significant proportion may be salvaged by surgery.
  • [MeSH-major] Cervix Uteri / pathology. Salvage Therapy. Uterine Cervical Neoplasms
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Anesthesia, General. Biopsy. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Adenosquamous / radiotherapy. Carcinoma, Adenosquamous / surgery. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy / methods. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm, Residual. Retrospective Studies. Survival Analysis


86. Lange TS, Kim KK, Singh RK, Strongin RM, McCourt CK, Brard L: Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. PLoS One; 2008 May 28;3(5):e2303
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iron(III)-salophene: an organometallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells.
  • BACKGROUND: In this pioneer study to the biological activity of organometallic compound Iron(III)-salophene (Fe-SP) the specific effects of Fe-SP on viability, morphology, proliferation, and cell-cycle progression on platinum-resistant ovarian cancer cell lines were investigated.
  • METHODOLOGY/PRINCIPAL FINDINGS: Fe-SP displayed selective cytotoxicity against SKOV-3 and OVCAR-3 (ovarian epithelial adenocarcinoma) cell lines at concentrations between 100 nM and 1 microM, while the viability of HeLa cells (epithelial cervix adenocarcinoma) or primary lung or skin fibroblasts was not affected.
  • When intra-peritoneally applied to rats Fe-SP did not show any systemic toxicity at concentrations that in preliminary trials were determined to be chemotherapeutic relevant doses in a rat ovarian cancer cell model.
  • CONCLUSION/SIGNIFICANCE: The present report suggests that Fe-SP is a potent growth-suppressing agent in vitro for cell lines derived from ovarian cancer and a potential therapeutic drug to treat such tumors in vivo.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 1998 Aug 28;281(5381):1312-6 [9721091.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33533-9 [9837934.001]
  • [Cites] Leukemia. 1999 Jul;13(7):1037-45 [10400419.001]
  • [Cites] Nat Cell Biol. 1999 Jul;1(3):E73-9 [10559915.001]
  • [Cites] J Clin Invest. 1999 Dec;104(12):1645-53 [10606615.001]
  • [Cites] Nucleic Acids Res. 1999 Nov 1;27(21):4160-6 [10518606.001]
  • [Cites] J Med Chem. 2004 Nov 18;47(24):5837-46 [15537341.001]
  • [Cites] Free Radic Biol Med. 2005 Jan 1;38(1):58-69 [15589372.001]
  • [Cites] Biochem Pharmacol. 2005 Apr 1;69(7):1009-39 [15763539.001]
  • [Cites] J Inorg Biochem. 2005 Jul;99(7):1433-40 [15878622.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 27;103(26):9756-60 [16785432.001]
  • [Cites] Arch Pharm (Weinheim). 2007 Mar;340(3):117-26 [17315259.001]
  • [Cites] Biochem Pharmacol. 2007 Jun 30;74(1):118-30 [17475222.001]
  • [Cites] Bioorg Med Chem Lett. 2007 Jul 1;17(13):3774-7 [17466518.001]
  • [Cites] Chem Biol Drug Des. 2007 Oct;70(4):302-10 [17937776.001]
  • [Cites] Genes Dev. 2007 Nov 15;21(22):2908-22 [18006686.001]
  • [Cites] J Inorg Biochem. 2008 Apr;102(4):740-7 [18180039.001]
  • [Cites] Gynecol Oncol. 2008 May;109(2):240-9 [18329084.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):153-83 [11294822.001]
  • [Cites] J Cell Biol. 2002 Apr 29;157(3):441-53 [11980919.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Jun;42(3):213-5 [12050015.001]
  • [Cites] J Med Chem. 2002 Sep 26;45(20):4549-58 [12238934.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):160-2 [14522248.001]
  • [Cites] Curr Cancer Drug Targets. 2004 Feb;4(1):65-75 [14965268.001]
  • [Cites] Oncogene. 2004 Apr 12;23(16):2774-84 [15077141.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):772-8 [15361183.001]
  • [Cites] Arch Biochem Biophys. 1994 Nov 15;315(1):74-81 [7979408.001]
  • [Cites] Eur J Clin Pharmacol. 1994;47(1):1-16 [7988618.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1821-8 [7997877.001]
  • [Cites] Curr Opin Cell Biol. 1995 Jun;7(3):337-43 [7662363.001]
  • [Cites] Bioorg Med Chem. 1996 Aug;4(8):1185-96 [8879539.001]
  • [Cites] Science. 1996 Dec 6;274(5293):1659-64 [8939847.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):789-92 [9404650.001]
  • [Cites] Bioconjug Chem. 1997 Nov-Dec;8(6):798-812 [9404652.001]
  • [Cites] Toxicology. 1997 Dec 31;124(3):179-92 [9482120.001]
  • [ErratumIn] PLoS ONE. 2008;3(7). doi: 10.1371/annotation/d97d24fc-aa07-40fd-88b2-6b2e050ddb31
  • (PMID = 18509533.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD043447; United States / NCRR NIH HHS / RR / P20 RR018728; United States / NCRR NIH HHS / RR / 1-P20RR018728
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ferric Compounds; 0 / Iron(III)-salophene; 49DFR088MY / Platinum
  • [Other-IDs] NLM/ PMC2386551
  •  go-up   go-down


87. Goyal M, Kodandapani S, Sharanabasappa SN, Palanki SD: Mesothelial cell inclusions mimicking adenocarcinoma in cervical lymph nodes in association with chylous effusion. Indian J Med Paediatr Oncol; 2010 Apr;31(2):62-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesothelial cell inclusions mimicking adenocarcinoma in cervical lymph nodes in association with chylous effusion.
  • Mesothelial cell inclusions in lymph nodes are of rare occurrence and can be mistaken as metastatic adenocarcinomas, mesothelioma or sinus histiocytosis.
  • We report a case of benign mesothelial cell inclusions in cervical lymph nodes, which was associated with chylous effusion, and immunohistochemistry revealed unusual weak cytoplasmic epithelial membrane antigen positivity in the cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1999 Oct;23(10):1264-9 [10524528.001]
  • [Cites] J Postgrad Med. 2008 Jul-Sep;54(3):230-1 [18626177.001]
  • [Cites] Histopathology. 1998 Dec;33(6):570-5 [9870153.001]
  • [Cites] Diagn Cytopathol. 1995 Jul;13(1):3-7 [7587872.001]
  • [Cites] Hum Pathol. 1998 Apr;29(4):339-46 [9563782.001]
  • [Cites] Am J Clin Pathol. 1990 Jun;93(6):741-8 [2161177.001]
  • (PMID = 21209767.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970937
  • [Keywords] NOTNLM ; Adenocarcinoma / chylous effusion / epithelial membrane antigen / mesothelial cell inclusions
  •  go-up   go-down


88. Roy D, Kulkarni A, Kulkarni S, Thakur MH, Maheshwari A, Tongaonkar HB: Transrectal ultrasound-guided biopsy of recurrent cervical carcinoma. Br J Radiol; 2008 Nov;81(971):902-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transrectal ultrasound-guided biopsy of recurrent cervical carcinoma.
  • The objective of this study was to evaluate the feasibility, safety and diagnostic accuracy of transrectal ultrasound (TRUS)-guided core biopsy for recurrent carcinoma of the uterine cervix in patients with non-diagnostic vaginal cytology and transvaginal punch biopsy.17 patients with clinical and imaging suspicion of recurrent carcinoma of the cervix, and with negative cytology and punch biopsy, were referred for TRUS-guided biopsy of a recurrent mass.
  • Data were collected with respect to demography, previous diagnosis, treatment received, size and location of the recurrent lesion, and biopsy results.
  • TRUS-guided biopsy was technically successful in all of the patients and provided histological diagnosis of recurrence in 16 patients.
  • In conclusion, TRUS-guided biopsy for recurrent cervical cancer is a feasible, safe and accurate method for establishing a histopathological diagnosis.
  • [MeSH-major] Adenocarcinoma / pathology. Biopsy, Needle / methods. Carcinoma, Small Cell / pathology. Cervix Uteri / pathology. Neoplasm Recurrence, Local / pathology. Uterine Cervical Neoplasms / pathology


89. An HJ, Kim KR, Kim IS, Kim DW, Park MH, Park IA, Suh KS, Seo EJ, Sung SH, Sohn JH, Yoon HK, Chang ED, Cho HI, Han JY, Hong SR, Ahn GH: Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study. Mod Pathol; 2005 Apr;18(4):528-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of human papillomavirus DNA in various histological subtypes of cervical adenocarcinoma: a population-based study.
  • The role of human papilloma virus (HPV) infection in the development of cervical carcinoma is well established, however, the prevalence of HPV DNA in cervical adenocarcinoma varies from study to study.
  • It appears to be caused by a number of factors, one of which is that cervical adenocarcinomas comprise a heterogeneous group of multiple subtypes.
  • To clarify the impact of HPV infection on the development of cervical adenocarcinoma with diverse histological subtypes, we performed a population-based study in Korean women from 15 different institutes for the status of HPV infection in adenocarcinoma of uterine cervix.
  • A total of 432 cervical adenocarcinomas from 1997 to 2001 were reviewed and classified according to the modified WHO classification.
  • The overall prevalence of HPV infection in cervical adenocarcinoma was 90%.
  • The infection of HPV 16 and/or HPV 18 accounted for 78% of HPV-positive adenocarcinomas.
  • The HPV DNA was rarely detected in minimal deviation adenocarcinoma.
  • In conclusion, HPV infection, mostly HPV 16 and HPV 18, is highly associated with most of the cervical adenocarcinomas, whereas endometrioid and villoglandular type have a different pattern of HPV infection status.
  • Minimal deviation adenocarcinoma does not seem to be related with HPV infection.
  • [MeSH-major] Adenocarcinoma / pathology. DNA, Viral / genetics. Papillomaviridae / genetics. Papillomavirus Infections / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15502807.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


90. Tarkkanen J, Auvinen E, Nieminen P, Malmi R, Vartiainen J, Timonen T, Laurila P, Räisänen I, Unnerus HA, Sakki A, Mattila P, Van Den Brule AV, Tapper AM: HPV DNA testing as an adjunct in the management of patients with low grade cytological lesions in Finland. Acta Obstet Gynecol Scand; 2007;86(3):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were 5/97 (5.2%) high grade lesions, which were HC2-negative but pap-positive, including 1 cervical adenocarcinoma in situ.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / diagnosis. DNA, Viral / analysis. Papillomaviridae / isolation & purification. Uterine Cervical Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17364315.001).
  • [ISSN] 0001-6349
  • [Journal-full-title] Acta obstetricia et gynecologica Scandinavica
  • [ISO-abbreviation] Acta Obstet Gynecol Scand
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


91. Sullivan LM, Smolkin ME, Frierson HF Jr, Galgano MT: Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology. Am J Surg Pathol; 2008 Nov;32(11):1608-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive evaluation of CDX2 in invasive cervical adenocarcinomas: immunopositivity in the absence of overt colorectal morphology.
  • In addition to staining adenocarcinomas of the alimentary system, studies have demonstrated CDX2 positivity in a percentage of ovarian mucinous and endometrioid tumors, carcinoids, and some adenocarcinomas of other sites such as the urinary bladder, prostate, lung, and pancreas.
  • However, CDX2 immunostaining in cervical adenocarcinomas has not been examined in detail with comparison to important clinicopathologic characteristics including histopathologic subtype, tumor stage, and patient follow-up.
  • In this study of 81 invasive cervical adenocarcinomas, 24 of the cases (30%) demonstrated nuclear positivity.
  • Our results indicate that cervical adenocarcinomas can show nuclear immunopositivity for CDX2 even in the absence of overt morphologic features of colorectal differentiation.
  • The frequency and pattern of CDX2 staining in the more common histologic subtypes of cervical adenocarcinoma (endocervical usual-type and endometrioid) is parallel to that which is seen for adenocarcinomas of the upper gastrointestinal tract and pancreaticobiliary system.
  • [MeSH-major] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Intestine, Large / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753946.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins
  •  go-up   go-down


92. Dalla Nora LC, Azara CZ, Pace EL, Martins CM, Zeferino LC, Westin MC, Derchain SF, Rabelo-Santos SH: Cytomorphological criteria, subclassifications of endocervical glandular cell abnormalities, and histopathological outcome: a frequency study. Diagn Cytopathol; 2010 Nov;38(11):806-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to evaluate the frequency and the significance of cytomorphological criteria defined in studies as being predictive of neoplasia in cervical smears of women with a cytological diagnosis of atypical glandular cells (AGC) or adenocarcinoma in situ (AIS).
  • The criteria analyzed and classified as present or absent in cervical smears previously classified as AGC-NOS (not otherwise specified), AGC-FN (favor neoplasia), or AIS were as follows: irregular nuclear membranes; scanty cytoplasm; dyskeratotic cells; increased nuclear/cytoplasmic ratio; nucleoli; overlapping; papillary clusters, feathering; loss of polarity; nuclear enlargement; coarsely granular chromatin; and pseudostratified strips.
  • Coarsely granular chromatin was observed in 62.5% of cases with a diagnosis of neoplasia.
  • Loss of polarity and coarsely granular chromatin were significantly associated with neoplastic diagnosis considering all subcategories of glandular abnormalities diagnosis.
  • In AGC-SOE subclassification, coarsely granular chromatin was significantly associated with neoplastic diagnosis.
  • The presence of nucleoli was significantly associated with neoplastic diagnosis in cervical smears qualified as AGC-FN and AIS.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


93. Sasajima Y, Mikami Y, Kaku T, Kiyokawa T, Ohishi Y, Hamada T, Sasaki T, Fujita H, Moriya T, Kasamatsu T, Tsuda H: Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix. Histopathology; 2008 Oct;53(4):487-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gross features of lobular endocervical glandular hyperplasia in comparison with minimal-deviation adenocarcinoma and stage Ib endocervical-type mucinous adenocarcinoma of the uterine cervix.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology


94. Van Calsteren K, Hanssens M, Moerman P, Orye G, Bielen D, Vergote I, Amant F: Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy. Acta Obstet Gynecol Scand; 2008;87(2):250-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful conservative treatment of endocervical adenocarcinoma stage Ib1 diagnosed early in pregnancy.
  • Traditionally when cervical cancer is diagnosed during the first trimester of pregnancy, oncological treatment is given priority despite the pregnant state.
  • A 32-year-old primigravida was diagnosed with invasive endocervical adenocarcinoma stage Ib1 at 8 weeks' gestation.
  • As the patient wanted to preserve the pregnancy, an amputation of the anterior cervix and retroperitoneal pelvic lymphadenectomy were performed.
  • In the absence of poor prognostic markers, we decided to adopt a conservative approach for cervical adenocarcinoma in a pregnant patient at 8 weeks' gestation.
  • [MeSH-major] Adenocarcinoma / surgery. Early Diagnosis. Pregnancy Complications, Neoplastic / surgery. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Cervix Uteri / surgery. Female. Humans. Lymph Node Excision. Pregnancy. Pregnancy Trimester, First


95. Yoo KJ, Lee HJ, Lee H, Lee KY, Lee SH, Chung HM, Baek KH: Expression and functional analyses of mHAUSP regulating apoptosis of cervical adenocarcinoma cells. Int J Oncol; 2005 Jul;27(1):97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and functional analyses of mHAUSP regulating apoptosis of cervical adenocarcinoma cells.
  • [MeSH-major] Apoptosis. Endopeptidases / biosynthesis. Endopeptidases / physiology. Gene Expression Regulation, Developmental. Gene Expression Regulation, Neoplastic. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology


96. Bai P, Ma Y, Li W, Zhang R: [Surgical intervention for the central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2010 Jan;32(1):52-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical intervention for the central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy].
  • OBJECTIVE: To evaluate the results of surgical treatment for central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy.
  • METHODS: Forty-seven patients were diagnosed having central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy.
  • CONCLUSION: For some patients with central recurrence or persistent local lesion of uterine cervical carcinoma following full-dose radiotherapy, surgical intervention may achieve long time survival.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Hysterectomy / methods. Uterine Cervical Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Brachytherapy. Cervix Uteri / pathology. Cervix Uteri / surgery. Cesium Radioisotopes / therapeutic use. Female. Follow-Up Studies. Humans. Iridium Radioisotopes / therapeutic use. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate. Young Adult


97. Lin Z, Gao M, Zhang X, Kim YS, Lee ES, Kim HK, Kim I: The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions. J Cancer Res Clin Oncol; 2005 Jun;131(6):364-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The hypermethylation and protein expression of p16 INK4A and DNA repair gene O6-methylguanine-DNA methyltransferase in various uterine cervical lesions.
  • PURPOSE: This study is aimed at investigating the significance of gene promoter methylation status and protein expression of p16 INK4A and O6-methylguanine-DNA methyltransferase (MGMT) in the various uterine cervical lesions.
  • MATERIALS AND METHODS: Methylation status by using methylation-specific polymerase chain reaction (MS-PCR) and protein expression by using immunohistochemistry for p16 INK4A and MGMT genes were performed in cervical squamous intraepithelial neoplasms (CIN), invasive squamous cell carcinomas (SCC), adenocarcinomas and non-neoplastic cervices.
  • RESULTS: None of 20 non-neoplastic cervices showed p16 INK4A and MGMT gene hypermethylation, whereas at least one of these genes was hypermethylated with 50.0% (5/10) of CIN I, 65.0% (13/20) of CIN II-III, 70.2% (33/47) of SCC and 85.0% (17/20) of adenocarcinoma. p16 INK4A protein was totally negative in non-neoplastic cervices, but positive with 90.0% of CIN I, 100% of CIN II-III and adenocarcinoma, and 78.7% of SCC.
  • MGMT protein was expressed in 10% of non-neoplastic cervices, but significantly increased in SCC (42.5%) and adenocarcinoma (70.0%).
  • CONCLUSIONS: The hypermethylation of p16 INK4A and MGMT genes in the uterine cervix may indicate the presence of malignant cells, and p16 INK4A immunostaining is useful in grading CIN and diagnosing invasive SCC and adenocarcinoma.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA Methylation. O(6)-Methylguanine-DNA Methyltransferase / genetics. Promoter Regions, Genetic. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / genetics. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Cervix Uteri / metabolism. DNA / metabolism. DNA Repair. Female. Gene Silencing. Humans. Immunoenzyme Techniques. Neoplasm Invasiveness / genetics. Neoplasm Invasiveness / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1517-23 [14562026.001]
  • [Cites] Lancet Oncol. 2002 Jan;3(1):11-6 [11905599.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6289-93 [7603984.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2002 May;43(5):1344-9 [11980845.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):371-9 [11986189.001]
  • [Cites] Neurol Res. 2003 Apr;25(3):241-8 [12739231.001]
  • [Cites] Gynecol Oncol. 1997 May;65(2):319-24 [9159345.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):939-42 [11221887.001]
  • [Cites] Diagn Mol Pathol. 1998 Dec;7(6):324-30 [10207671.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):435-40 [15099958.001]
  • [Cites] Mol Carcinog. 1999 Feb;24(2):90-8 [10078936.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11891-6 [9751761.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4531-5 [7553622.001]
  • [Cites] J Natl Cancer Inst. 1998 Mar 18;90(6):433-9 [9521167.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5360-8 [9393761.001]
  • [Cites] J Biol Chem. 1983 Feb 25;258(4):2327-33 [6822564.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):826-32 [10814678.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):200-7 [15279712.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2981-4 [12912945.001]
  • [Cites] J Natl Cancer Inst. 2002 Sep 18;94(18):1406-14 [12237286.001]
  • [Cites] Am J Obstet Gynecol. 2004 Mar;190(3):674-9 [15041998.001]
  • [Cites] Int J Cancer. 2001 Apr 15;92(2):276-84 [11291057.001]
  • [Cites] Cell. 1981 Apr;24(1):33-40 [6263490.001]
  • [Cites] Clin Cancer Res. 2001 Jul;7(7):1982-6 [11448914.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):584-9 [11297252.001]
  • [Cites] Cancer Chemother Pharmacol. 1996;37(6):547-55 [8612308.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Am J Surg Pathol. 2003 Feb;27(2):187-93 [12548164.001]
  • [Cites] Genes Dev. 1999 Jan 1;13(1):26-34 [9887097.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):69-72 [9662253.001]
  • [Cites] Pathol Int. 2002 May-Jun;52(5-6):375-83 [12100520.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3416-20 [8324751.001]
  • [Cites] Nat Med. 1995 Jul;1(7):686-92 [7585152.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):689-96 [15188135.001]
  • [Cites] J Natl Cancer Inst. 1992 Mar 4;84(5):337-40 [1738185.001]
  • [Cites] Oncology. 1999;56(1):83-7 [9885382.001]
  • [Cites] Virchows Arch. 2001 Jul;439(1):55-61 [11499840.001]
  • [Cites] Cell. 1988 Apr 8;53(1):3-4 [3280142.001]
  • [Cites] Trends Cell Biol. 1994 Jan;4(1):15-8 [14731824.001]
  • [Cites] Gynecol Oncol. 2001 Aug;82(2):299-304 [11531283.001]
  • [Cites] Clin Cancer Res. 1996 Mar;2(3):577-84 [9816206.001]
  • [Cites] J Gastrointest Surg. 2003 Dec;7(8):1004-14; discussion 1014 [14675710.001]
  • [Cites] Carcinogenesis. 1998 Jul;19(7):1247-50 [9683184.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):807-10 [10029067.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):591-3 [9485004.001]
  • [Cites] Cancer Res. 1991 Aug 15;51(16):4131-4 [1868433.001]
  • (PMID = 15785933.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 9007-49-2 / DNA; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


98. Alrawi SJ, Winston J, Tan D, Gibbs J, Loree TR, Hicks W, Rigual N, Lorè JM Jr: Primary adenocarcinoma of cervical esophagus. J Exp Clin Cancer Res; 2005 Jun;24(2):325-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adenocarcinoma of cervical esophagus.
  • Most upper esophageal malignancies are squamous cell carcinomas, rarely adenocarcinomas arising from Barrett's esophagus and very rarely adenocarcinomas from heterotopic gastric mucosa without evidence of Barrett's especially in the cervical part of the esophagus.
  • We report a case of adenocarcinoma of the polypoid type in the upper esophagus (cervical esophagus) arising from ectopic gastric mucosa, in a 60 year-old man who presented with progressive dysphagia.
  • Accurate diagnosis by esophagogram revealed a large mass in the cervical esophagus; CAT scan showed intraluminal mass at the level of thoracic inlet, esophagogastroscopy showed a fleshy polyp (3.2cm x 3.0cm) at 20 cm from the incisors with a biopsy confirming moderately differentiated adenocarcinoma with no evidence of Barrett's esophagus.
  • Through a left cervical approach and resection of medial third of clavicle, the tumor was removed by partial esophagectomy followed by lymph node dissection, and proved to be T1NOMO, stage I (AJCC staging 6th ed.).
  • It seems this tumor has a much better prognosis than adenocarcinomas arising from Barrett's.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16110768.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


99. Nayar AG, Cross PA, Bulmer JN, Deen S, El-Sherif A: Comparison of examination of the entire uterine cervix with routine cervical sampling in hysterectomy specimens from women with endometrial cancer. J Clin Pathol; 2008 May;61(5):621-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of examination of the entire uterine cervix with routine cervical sampling in hysterectomy specimens from women with endometrial cancer.
  • BACKGROUND: Cervical involvement by endometrial cancer alters the FIGO stage and determines clinical management, but there are no accepted guidelines for cervical sampling of these cases.
  • AIM: To assess whether sampling more than two "routine" blocks of the cervix (anterior and posterior) alters the pathological staging of hysterectomy specimens for endometrial cancer.
  • METHODS: Histological involvement of the cervix was prospectively compared in hysterectomies performed for proven endometrial cancer (n = 61).
  • Specimens had two "routine" blocks taken from anterior and posterior cervix; all of the remaining cervix was also processed for histological assessment.
  • RESULTS: 61 cases of endometrial cancer had the entire uterine cervix processed.
  • There were 54 cases of endometrioid adenocarcinoma and 7 special types.
  • Twelve cases had cervical involvement (stage 2A or 2B), and seven cases were stage 3A or above, of which three also had cervical involvement.
  • In none of the 61 cases did the additional cervical blocks (n = 544) taken alter the staging made on the "routine" blocks.
  • CONCLUSION: Sampling of two blocks from the cervix appears sufficient for histological staging of endometrial cancer in hysterectomy specimens.
  • [MeSH-major] Adenocarcinoma / pathology. Cervix Uteri / pathology. Endometrial Neoplasms / pathology. Hysterectomy


100. Cheeti S, Lee CH: The involvement of intracellular calcium in the MCT-mediated uptake of lactic acid by HeLa cells. Mol Pharm; 2010 Feb 1;7(1):169-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The changes in intracellular pH (pH(in)) and MCT mediated uptake rates of L-lactic acid by HeLa cells, a human cervical adenocarcinoma cell line, were evaluated under the conditions, whose [Ca2+](in) concentrations were altered by various calcium modulators, such as EGTA-AM (a chelator), nifedipine (a Ca2+ channel antagonist) and A23187 (an ionophore).
  • An understanding of the role of [Ca2+](in) in the MCT mediated transport process could provide an efficient strategy to improve the systemic delivery of monocarboxylate substrates through the cervical mucosa.

  • Hazardous Substances Data Bank. Nifedipine .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. SODIUM .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Antimicrob Agents Chemother. 1992 Nov;36(11):2462-7 [1489189.001]
  • [Cites] Endocrinology. 1992 Sep;131(3):1125-33 [1324151.001]
  • [Cites] Biochim Biophys Acta. 1996 Jul 18;1275(1-2):127-32 [8688445.001]
  • [Cites] J Cell Sci. 1996 May;109 ( Pt 5):929-39 [8743940.001]
  • [Cites] Tohoku J Exp Med. 1996 Aug;179(4):291-4 [8944431.001]
  • [Cites] Biochem J. 1998 Jan 15;329 ( Pt 2):321-8 [9425115.001]
  • [Cites] J Am Coll Cardiol. 1999 Jan;33(1):242-9 [9935037.001]
  • [Cites] BJOG. 2005 Jun;112(6):754-8 [15924532.001]
  • [Cites] Int J Pharm. 2006 Nov 15;325(1-2):48-54 [16887304.001]
  • [Cites] Blood. 2007 May 1;109(9):3812-9 [17255361.001]
  • [Cites] Mol Cell Biochem. 2008 Mar;310(1-2):191-201 [18095144.001]
  • [Cites] BJU Int. 2008 Jun;101 Suppl 4:8-15 [18430116.001]
  • [Cites] J Nucl Med. 2008 Jun;49 Suppl 2:24S-42S [18523064.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 2000;17(5):509-55 [11108158.001]
  • [Cites] Reprod Fertil Dev. 2000;12(3-4):201-7 [11302430.001]
  • [Cites] Am J Obstet Gynecol. 2001 Aug;185(2):375-9 [11518895.001]
  • [Cites] Antimicrob Agents Chemother. 2002 May;46(5):1375-80 [11959571.001]
  • [Cites] FEBS Lett. 2002 Jun 19;521(1-3):205-10 [12067706.001]
  • [Cites] Am J Physiol Cell Physiol. 2003 Dec;285(6):C1527-36 [12954600.001]
  • [Cites] Annu Rev Biochem. 1976;45:501-30 [786156.001]
  • [Cites] J Biol Chem. 1987 Jan 15;262(2):649-53 [3027061.001]
  • [Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):123-7 [1309603.001]
  • [Cites] Biochem J. 1995 Nov 15;312 ( Pt 1):293-300 [7492327.001]
  • (PMID = 19905008.001).
  • [ISSN] 1543-8392
  • [Journal-full-title] Molecular pharmaceutics
  • [ISO-abbreviation] Mol. Pharm.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / HD040784-01; United States / NICHD NIH HHS / HD / R15 HD040784; United States / NICHD NIH HHS / HD / HD 40784-01; United States / NICHD NIH HHS / HD / R15 HD040784-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Chelating Agents; 0 / DNA Primers; 0 / Ionophores; 0 / Monocarboxylic Acid Transporters; 0 / RNA, Messenger; 0 / Sodium-Hydrogen Antiporter; 0 / Symporters; 0 / monocarboxylate transport protein 1; 33X04XA5AT / Lactic Acid; 37H9VM9WZL / Calcimycin; 526U7A2651 / Egtazic Acid; 99590-86-0 / EGTA acetoxymethyl ester; 9NEZ333N27 / Sodium; I9ZF7L6G2L / Nifedipine; SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS159719; NLM/ PMC2815175
  •  go-up   go-down






Advertisement